フルジェントジェネティクスの四半期報告

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

0001674930Q1--12-31falsehttp://fasb.org/srt/2024#ChiefExecutiveOfficerMemberhttp://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMemberhttp://fasb.org/srt/2024#ChiefExecutiveOfficerMemberhttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#RelatedPartyMemberhttp://fasb.org/us-gaap/2024#RelatedPartyMember0001674930flgt:LaboratoryServicesMember2025-03-310001674930us-gaap:OperatingSegmentsMemberflgt:LaboratoryServicesMemberflgt:PrecisionDiagnosticsMember2025-01-012025-03-310001674930us-gaap:OperatingSegmentsMemberflgt:LaboratoryServicesMember2025-03-310001674930flgt:LongTermEquitySecuritiesMemberflgt:PreferredStockOfPrivatelyHeldCompanyMember2024-12-310001674930us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberflgt:CustomerOneMember2025-01-012025-03-310001674930us-gaap:FairValueMeasurementsRecurringMemberflgt:USAgencyDebtSecuritiesMember2024-12-310001674930us-gaap:RetainedEarningsMember2024-01-012024-03-310001674930flgt:LaboratoryServicesMember2024-12-310001674930us-gaap:OperatingSegmentsMember2025-03-310001674930flgt:LaboratoryServicesMemberus-gaap:CustomerRelationshipsMember2024-12-310001674930us-gaap:BuildingMembersrt:MaximumMember2025-03-310001674930us-gaap:USGovernmentDebtSecuritiesMemberflgt:DebtSecuritiesDueAfterOneYearThroughFiveYearsMember2024-12-310001674930us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001674930us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001674930us-gaap:LandImprovementsMembersrt:MaximumMember2025-03-310001674930flgt:LaboratoryServicesMemberus-gaap:TradeNamesMember2025-03-310001674930flgt:InstallmentSaleContractMember2025-01-012025-03-310001674930us-gaap:CommonStockMember2023-12-310001674930flgt:AccountingStandardUpdate201409Memberflgt:ClinicalInstitutionalContractsMember2024-01-012024-03-310001674930us-gaap:FairValueMeasurementsRecurringMember2025-03-310001674930us-gaap:OperatingSegmentsMembercountry:US2024-12-310001674930us-gaap:FurnitureAndFixturesMember2025-03-310001674930us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001674930flgt:LaboratoryServicesMemberflgt:RoyaltyFreeTechnologyMember2025-01-012025-03-310001674930us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001674930us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001674930srt:DirectorMemberflgt:AnpTechnologiesIncorporationMember2025-03-310001674930flgt:AssetsNotYetPlacedInServiceMember2025-03-310001674930flgt:EliminationsAndReconcilingItemsMember2024-01-012024-03-310001674930us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2024-12-310001674930flgt:InstallmentSaleContractMemberus-gaap:OtherNoncurrentLiabilitiesMember2025-03-310001674930us-gaap:FairValueMeasurementsRecurringMemberflgt:PreferredStockOfPrivatelyHeldCompanyMember2025-03-310001674930us-gaap:CorporateDebtSecuritiesMemberflgt:DebtSecuritiesDueAfterOneYearThroughFiveYearsMember2025-03-310001674930us-gaap:CorporateDebtSecuritiesMemberflgt:ShortTermMarketableSecuritesMember2025-03-310001674930us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001674930flgt:Covid19Memberus-gaap:OperatingSegmentsMemberflgt:LaboratoryServicesMember2024-01-012024-03-310001674930flgt:TherapeuticDevelopmentMemberus-gaap:MaterialReconcilingItemsMember2024-01-012024-03-310001674930srt:MaximumMemberus-gaap:ComputerEquipmentMember2025-03-310001674930us-gaap:OperatingSegmentsMembercountry:CN2025-01-012025-03-310001674930us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001674930us-gaap:FairValueMeasurementsRecurringMemberflgt:PreferredStockOfPrivatelyHeldCompanyMember2024-12-310001674930us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2024-12-310001674930flgt:DebtSecuritiesDueAfterOneYearThroughFiveYearsMemberflgt:YankeeDebtSecuritiesMember2024-12-310001674930us-gaap:DebtSecuritiesMember2025-03-310001674930flgt:LaboratoryServicesMemberflgt:EliminationsAndReconcilingItemsMember2025-01-012025-03-310001674930us-gaap:BuildingImprovementsMembersrt:MaximumMember2025-03-310001674930us-gaap:ServiceAgreementsMemberflgt:ANPTechnologiesIncMember2024-01-012024-03-310001674930flgt:BiopharmaServicesMemberus-gaap:OperatingSegmentsMemberflgt:LaboratoryServicesMember2025-01-012025-03-310001674930us-gaap:ParentMember2024-01-012024-03-310001674930us-gaap:OperatingSegmentsMembercountry:US2025-01-012025-03-310001674930us-gaap:FairValueMeasurementsRecurringMember2024-12-310001674930flgt:LaboratoryServicesMemberus-gaap:MaterialReconcilingItemsMember2025-01-012025-03-310001674930us-gaap:AdditionalPaidInCapitalMember2025-03-310001674930flgt:ShortTermMarketableSecuritesMemberus-gaap:MunicipalBondsMember2024-12-3100016749302024-12-310001674930us-gaap:BuildingImprovementsMember2025-03-310001674930flgt:ANPTechnologiesIncMember2024-01-012024-03-310001674930flgt:LaboratoryServicesMemberflgt:RoyaltyFreeTechnologyMember2025-03-310001674930flgt:LaboratoryServicesMemberus-gaap:TradeNamesMember2024-12-310001674930us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberflgt:CustomerOneMember2024-01-012024-03-310001674930flgt:AutomobileMembersrt:MaximumMember2025-03-310001674930flgt:LongTermEquitySecuritiesMemberflgt:PreferredStockOfPrivatelyHeldCompanyMember2025-03-310001674930flgt:MedicalLabEquipmentMembersrt:MaximumMember2025-03-310001674930us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001674930us-gaap:OperatingSegmentsMembercountry:CN2024-01-012024-03-310001674930us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001674930us-gaap:USGovernmentDebtSecuritiesMemberflgt:ShortTermMarketableSecuritesMember2025-03-310001674930us-gaap:RetainedEarningsMember2024-03-310001674930flgt:AutomobileMember2024-12-310001674930flgt:LaboratoryServicesMemberflgt:PurchasedPatentMember2024-12-310001674930us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2025-03-310001674930us-gaap:MoneyMarketFundsMemberflgt:ShortTermMarketableSecuritesMember2024-12-310001674930us-gaap:CommonStockMember2025-01-012025-03-310001674930srt:MinimumMemberus-gaap:LandImprovementsMember2025-03-310001674930flgt:ClinicalPatientContractsMemberflgt:AccountingStandardUpdate201409Member2024-01-012024-03-310001674930us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001674930us-gaap:ParentMember2023-12-310001674930flgt:TherapeuticDevelopmentMemberus-gaap:OperatingSegmentsMember2024-12-310001674930flgt:TherapeuticDevelopmentMemberflgt:EliminationsAndReconcilingItemsMember2024-01-012024-03-310001674930flgt:HealthResourcesAndServicesAdministrationUninsuredProgramMember2020-01-012022-12-310001674930us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001674930us-gaap:OperatingSegmentsMembercountry:CN2024-12-310001674930us-gaap:AgencySecuritiesMemberflgt:DebtSecuritiesDueAfterOneYearThroughFiveYearsMember2024-12-310001674930us-gaap:MaterialReconcilingItemsMember2024-01-012024-03-310001674930us-gaap:NoncontrollingInterestMember2025-01-012025-03-310001674930us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2025-03-310001674930us-gaap:RetainedEarningsMember2025-01-012025-03-310001674930us-gaap:NoncontrollingInterestMember2024-12-310001674930flgt:LaboratoryServicesMemberus-gaap:CustomerRelationshipsMember2025-01-012025-03-310001674930flgt:AccountingStandardUpdate201409Member2025-01-012025-03-310001674930us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001674930flgt:MedicalLabEquipmentMembersrt:MinimumMember2025-03-310001674930us-gaap:SubsequentEventMember2025-05-020001674930flgt:DirectorAndOfficerMember2025-01-012025-03-310001674930us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001674930us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2024-12-310001674930flgt:ANPTechnologiesIncMember2025-03-3100016749302025-03-310001674930us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001674930flgt:TherapeuticDevelopmentMember2025-03-310001674930us-gaap:ParentMember2025-03-310001674930us-gaap:OperatingSegmentsMemberflgt:OtherCountriesMember2024-12-310001674930us-gaap:USGovernmentDebtSecuritiesMemberflgt:ShortTermMarketableSecuritesMember2024-12-310001674930us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001674930flgt:ANPTechnologiesIncMember2024-12-310001674930us-gaap:RetainedEarningsMember2023-12-310001674930us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001674930us-gaap:BuildingMember2024-12-3100016749302024-01-012024-03-310001674930us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001674930flgt:AutomobileMember2025-03-3100016749302023-12-310001674930us-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2025-01-012025-03-310001674930us-gaap:CommonStockMember2025-03-310001674930us-gaap:MoneyMarketFundsMemberflgt:ShortTermMarketableSecuritesMember2025-03-310001674930us-gaap:DebtSecuritiesMember2024-12-310001674930us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001674930us-gaap:NoncontrollingInterestMember2024-03-310001674930srt:MinimumMemberus-gaap:BuildingMember2025-03-310001674930flgt:InstitutionalCustomerMember2024-12-310001674930flgt:InProcessResearchDevelopmentMemberflgt:TherapeuticDevelopmentMember2024-12-310001674930flgt:MedicalLabEquipmentMember2025-03-310001674930us-gaap:CostOfSalesMember2025-01-012025-03-310001674930us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001674930us-gaap:OperatingSegmentsMemberflgt:LaboratoryServicesMember2024-12-310001674930us-gaap:OperatingSegmentsMember2024-12-310001674930srt:MinimumMemberus-gaap:SoftwareDevelopmentMember2025-03-310001674930us-gaap:ServiceAgreementsMemberflgt:ANPTechnologiesIncMember2025-01-012025-03-310001674930us-gaap:CommonStockMember2024-03-310001674930us-gaap:CorporateDebtSecuritiesMemberflgt:ShortTermMarketableSecuritesMember2024-12-310001674930flgt:SecInvestigationMember2024-12-310001674930us-gaap:OperatingSegmentsMemberflgt:LaboratoryServicesMemberflgt:PrecisionDiagnosticsMember2024-01-012024-03-310001674930us-gaap:ParentMember2024-12-310001674930us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberflgt:CustomerOneMember2024-01-012024-12-310001674930us-gaap:BuildingImprovementsMembersrt:MinimumMember2025-03-310001674930us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberflgt:YankeeDebtSecuritiesMember2024-12-310001674930flgt:AccountingStandardUpdate201409Member2024-01-012024-03-310001674930us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberflgt:YankeeDebtSecuritiesMember2025-03-310001674930flgt:LaboratoryServicesMemberus-gaap:CustomerRelationshipsMember2025-03-310001674930flgt:LaboratoryServicesMemberflgt:InPlaceLeaseIntangibleAssetsMember2024-12-310001674930us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2025-03-310001674930us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001674930us-gaap:OperatingSegmentsMemberflgt:Covid19Memberflgt:LaboratoryServicesMember2025-01-012025-03-310001674930flgt:LaboratoryInformationSystemPlatformMemberflgt:LaboratoryServicesMember2024-12-310001674930flgt:DebtSecuritiesDueAfterOneYearThroughFiveYearsMember2024-12-310001674930us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2025-03-310001674930us-gaap:OperatingSegmentsMemberflgt:LaboratoryServicesMemberflgt:AnatomicPathologyMember2024-01-012024-03-310001674930flgt:AssetsNotYetPlacedInServiceMember2024-12-310001674930us-gaap:OperatingSegmentsMembercountry:US2025-03-310001674930us-gaap:LeaseholdImprovementsMember2025-03-310001674930us-gaap:OperatingSegmentsMemberflgt:TherapeuticDevelopmentMember2024-01-012024-03-310001674930flgt:DebtSecuritiesDueAfterOneYearThroughFiveYearsMemberus-gaap:MunicipalBondsMember2024-12-310001674930us-gaap:USGovernmentDebtSecuritiesMemberflgt:DebtSecuritiesDueAfterOneYearThroughFiveYearsMember2025-03-310001674930flgt:LaboratoryInformationSystemPlatformMemberflgt:LaboratoryServicesMember2025-03-3100016749302025-04-280001674930us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001674930us-gaap:SellingAndMarketingExpenseMember2024-01-012024-03-310001674930flgt:LaboratoryServicesMemberus-gaap:TradeNamesMember2025-01-012025-03-310001674930us-gaap:CostOfSalesMember2024-01-012024-03-310001674930us-gaap:LandImprovementsMember2025-03-310001674930us-gaap:FairValueMeasurementsRecurringMemberflgt:YankeeDebtSecuritiesMember2024-12-310001674930us-gaap:LandMember2025-03-310001674930us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001674930us-gaap:OperatingSegmentsMemberflgt:TherapeuticDevelopmentMember2025-01-012025-03-310001674930flgt:AircraftMember2024-12-310001674930flgt:DebtSecuritiesDueAfterOneYearThroughFiveYearsMemberus-gaap:MunicipalBondsMember2025-03-310001674930flgt:ShortTermMarketableSecuritesMember2024-12-310001674930us-gaap:OperatingSegmentsMemberflgt:LaboratoryServicesMember2024-01-012024-03-310001674930flgt:AccountingStandardUpdate201409Memberflgt:ClinicalInstitutionalContractsMember2025-01-012025-03-310001674930us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001674930us-gaap:MaterialReconcilingItemsMember2025-01-012025-03-310001674930flgt:DebtSecuritiesDueAfterOneYearThroughFiveYearsMember2025-03-310001674930flgt:ShortTermMarketableSecuritesMemberus-gaap:AgencySecuritiesMember2025-03-310001674930us-gaap:OperatingSegmentsMember2024-01-012024-03-310001674930us-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310001674930flgt:ClinicalInsuranceContractsMemberflgt:AccountingStandardUpdate201409Member2024-01-012024-03-310001674930flgt:ShortTermMarketableSecuritesMemberus-gaap:MunicipalBondsMember2025-03-310001674930us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberflgt:USAgencyDebtSecuritiesMember2025-03-310001674930us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberflgt:PreferredStockOfPrivatelyHeldCompanyMember2024-12-310001674930us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2024-12-310001674930us-gaap:RetainedEarningsMember2024-12-310001674930us-gaap:OperatingSegmentsMemberflgt:LaboratoryServicesMemberflgt:AnatomicPathologyMember2025-01-012025-03-310001674930us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001674930flgt:TherapeuticDevelopmentMemberflgt:EliminationsAndReconcilingItemsMember2025-01-012025-03-310001674930us-gaap:OperatingSegmentsMembercountry:US2024-01-012024-03-310001674930us-gaap:FairValueMeasurementsRecurringMemberflgt:USAgencyDebtSecuritiesMember2025-03-310001674930us-gaap:LandMember2024-12-310001674930us-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2025-03-310001674930flgt:LaboratoryServicesMemberflgt:PurchasedPatentMember2025-03-310001674930flgt:LaboratoryServicesMemberflgt:InPlaceLeaseIntangibleAssetsMember2025-03-310001674930flgt:LaboratoryServicesMemberflgt:InPlaceLeaseIntangibleAssetsMember2025-01-012025-03-310001674930us-gaap:OperatingSegmentsMember2025-01-012025-03-310001674930us-gaap:OperatingSegmentsMembercountry:CN2025-03-310001674930flgt:InProcessResearchDevelopmentMemberflgt:TherapeuticDevelopmentMember2025-03-310001674930flgt:EliminationsAndReconcilingItemsMember2025-01-012025-03-310001674930us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001674930flgt:ShortTermMarketableSecuritesMemberus-gaap:USTreasuryBillSecuritiesMember2025-03-310001674930flgt:GeneralEquipmentMember2025-03-310001674930us-gaap:OperatingSegmentsMemberflgt:OtherCountriesMember2025-03-310001674930flgt:GeneralEquipmentMember2024-12-310001674930flgt:LaboratoryServicesMemberflgt:PurchasedPatentMember2025-01-012025-03-3100016749302025-01-012025-03-310001674930flgt:LaboratoryServicesMemberflgt:RoyaltyFreeTechnologyMember2024-12-310001674930us-gaap:ParentMember2025-01-012025-03-310001674930us-gaap:OperatingSegmentsMemberflgt:OtherCountriesMember2025-01-012025-03-310001674930us-gaap:SoftwareDevelopmentMember2024-12-310001674930srt:MinimumMemberus-gaap:ComputerEquipmentMember2025-03-310001674930flgt:AircraftMember2025-03-310001674930flgt:ShortTermMarketableSecuritesMemberus-gaap:USTreasuryBillSecuritiesMember2024-12-310001674930flgt:BiopharmaServicesMemberus-gaap:OperatingSegmentsMemberflgt:LaboratoryServicesMember2024-01-012024-03-310001674930us-gaap:BuildingMember2025-03-310001674930us-gaap:NoncontrollingInterestMember2023-12-310001674930us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001674930us-gaap:CommonStockMember2024-12-310001674930srt:MaximumMemberus-gaap:SoftwareDevelopmentMember2025-03-310001674930us-gaap:AdditionalPaidInCapitalMember2023-12-310001674930flgt:ClinicalPatientContractsMemberflgt:AccountingStandardUpdate201409Member2025-01-012025-03-310001674930us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001674930us-gaap:OperatingSegmentsMemberflgt:OtherCountriesMember2024-01-012024-03-310001674930us-gaap:LeaseholdImprovementsMember2024-12-310001674930srt:MinimumMemberflgt:AutomobileMember2025-03-310001674930flgt:ContingentlyIssuableSharesMember2024-01-012024-03-310001674930us-gaap:ComputerEquipmentMember2024-12-3100016749302022-03-310001674930flgt:InstallmentSaleContractMember2025-03-310001674930us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2025-03-310001674930us-gaap:SubsequentEventMember2025-04-012025-05-020001674930srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2025-03-310001674930us-gaap:AdditionalPaidInCapitalMember2024-03-310001674930us-gaap:BuildingImprovementsMember2024-12-310001674930flgt:LaboratoryServicesMemberus-gaap:MaterialReconcilingItemsMember2024-01-012024-03-310001674930flgt:LongTermEquitySecuritiesMember2025-03-310001674930flgt:ClinicalInsuranceContractsMemberflgt:AccountingStandardUpdate201409Member2025-01-012025-03-310001674930us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberflgt:USAgencyDebtSecuritiesMember2024-12-310001674930flgt:LaboratoryServicesMemberflgt:EliminationsAndReconcilingItemsMember2024-01-012024-03-310001674930us-gaap:FairValueMeasurementsRecurringMemberflgt:YankeeDebtSecuritiesMember2025-03-310001674930flgt:InsuranceCustomerMember2024-12-3100016749302024-03-310001674930flgt:TherapeuticDevelopmentMember2024-12-310001674930us-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2024-12-310001674930us-gaap:SoftwareDevelopmentMember2025-03-310001674930flgt:InstitutionalCustomerMember2025-03-310001674930flgt:LongTermEquitySecuritiesMember2024-12-310001674930us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberflgt:PreferredStockOfPrivatelyHeldCompanyMember2025-03-310001674930flgt:InsuranceCustomerMember2025-03-310001674930flgt:ANPTechnologiesIncMember2025-01-012025-03-310001674930us-gaap:ComputerEquipmentMember2025-03-310001674930us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberflgt:CustomerOneMember2025-01-012025-03-310001674930us-gaap:AdditionalPaidInCapitalMember2024-12-310001674930us-gaap:FurnitureAndFixturesMember2024-12-310001674930us-gaap:LandImprovementsMember2024-12-310001674930srt:MaximumMember2025-03-310001674930us-gaap:OperatingSegmentsMemberflgt:LaboratoryServicesMember2025-01-012025-03-310001674930us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001674930us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-310001674930us-gaap:CorporateDebtSecuritiesMemberflgt:DebtSecuritiesDueAfterOneYearThroughFiveYearsMember2024-12-310001674930flgt:DebtSecuritiesDueAfterOneYearThroughFiveYearsMemberflgt:YankeeDebtSecuritiesMember2025-03-310001674930us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001674930flgt:ShortTermMarketableSecuritesMemberus-gaap:AgencySecuritiesMember2024-12-310001674930srt:MaximumMember2025-01-012025-03-310001674930flgt:TherapeuticDevelopmentMemberus-gaap:MaterialReconcilingItemsMember2025-01-012025-03-310001674930flgt:ShortTermMarketableSecuritesMember2025-03-310001674930flgt:MedicalLabEquipmentMember2024-12-310001674930flgt:LaboratoryInformationSystemPlatformMemberflgt:LaboratoryServicesMember2025-01-012025-03-310001674930us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001674930us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001674930flgt:TherapeuticDevelopmentMemberus-gaap:OperatingSegmentsMember2025-03-310001674930us-gaap:SellingAndMarketingExpenseMember2025-01-012025-03-310001674930us-gaap:CommonStockMember2024-01-012024-03-310001674930us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001674930us-gaap:RetainedEarningsMember2025-03-310001674930us-gaap:AgencySecuritiesMemberflgt:DebtSecuritiesDueAfterOneYearThroughFiveYearsMember2025-03-310001674930us-gaap:ParentMember2024-03-310001674930us-gaap:NoncontrollingInterestMember2025-03-310001674930us-gaap:NoncontrollingInterestMember2024-01-012024-03-310001674930us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-31xbrli:pureflgt:Customerxbrli:sharesiso4217:USDxbrli:sharesiso4217:USDflgt:Segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-37894

FULGENT GENETICS, INC.

(Exact name of registrant as specified in its charter)


Delaware	81-2621304
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

4399 Santa Anita Avenue El Monte, CA	91731
(Address of principal executive offices)	(Zip Code)

(626) 350-0537

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	FLGT	The Nasdaq Stock Market (Nasdaq Global Market)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of April 28, 2025, there were 30,443,595 outstanding shares of the registrant’s common stock.

Table of Contents


	Page
PART I—FINANCIAL INFORMATION	1
Item 1. Financial Statements (Unaudited)	1
Condensed Consolidated Balance Sheets	1
Condensed Consolidated Statements of Operations	2
Condensed Consolidated Statements of Comprehensive Loss	3
Condensed Consolidated Statements of Stockholders’ Equity	4
Condensed Consolidated Statements of Cash Flows	6
Notes to the Condensed Consolidated Financial Statements	7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	26
Item 3. Quantitative and Qualitative Disclosures About Market Risk	32
Item 4. Controls and Procedures	32
PART II—OTHER INFORMATION	33
Item 1. Legal Proceedings	33
Item 1A. Risk Factors	33
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	33
Item 5. Other Information	34
Item 6. Exhibits	34
Exhibit Index	35
Signatures	36

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

FULGENT GENETICS, INC.

Condensed Consolidated Balance Sheets

(in thousands, except par value data)

(unaudited)


	March 31, 2025			December 31, 2024
Assets
Current assets
Cash and cash equivalents	$	67,281		$	55,144
Marketable securities		253,040			202,962
Trade accounts receivable, net of allowance for credit losses of $20,935 as of March 31, 2025, and $20,458 as of December 31, 2024		71,478			69,021
Other current assets		24,985			26,444
Total current assets		416,784			353,571
Marketable securities, long-term		494,111			570,351
Intangible assets, net		133,009			134,978
Fixed assets, net		107,077			105,549
Goodwill		22,055			22,055
Other long-term assets		32,708			33,460
Total assets	$	1,205,744		$	1,219,964
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable	$	18,238		$	18,364
Accrued liabilities		16,689			24,279
Customer deposit		27,695			27,610
Contract liabilities		2,817			2,234
Notes payable, current		476			412
Total current liabilities		65,915			72,899
Deferred tax liabilities		6,237			6,370
Unrecognized tax benefits		4,700			4,563
Other long-term liabilities		6,122			6,973
Total liabilities		82,974			90,805
Commitments and Contingencies (Note 8)
Stockholders’ equity
Common stock, $0.0001 par value per share, 50,000 shares authorized, 33,863 shares issued and 30,621 shares outstanding as of March 31, 2025, and 33,614 shares issued and 30,841 shares outstanding as of December 31, 2024		3			3
Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding as of March 31, 2025, and December 31, 2024		—			—
Additional paid-in capital		543,903			543,126
Accumulated other comprehensive income (loss)		4,335			(368	)
Retained earnings		578,937			590,467
Total Fulgent stockholders’ equity		1,127,178			1,133,228
Noncontrolling interest		(4,408	)		(4,069	)
Total stockholders’ equity		1,122,770			1,129,159
Total liabilities and stockholders’ equity	$	1,205,744		$	1,219,964

The accompanying notes are an integral part of these condensed consolidated financial statements.

FULGENT GENETICS, INC.

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

(unaudited)


	Three Months Ended March 31,
	2025			2024
Revenue	$	73,463		$	64,485
Cost of revenue		45,117			42,381
Gross profit		28,346			22,104
Operating expenses
Research and development		12,395			11,434
Selling and marketing		8,465			8,989
General and administrative		25,291			21,489
Amortization of intangible assets		1,990			1,990
Total operating expenses		48,141			43,902
Operating loss		(19,795	)		(21,798	)
Other income (expenses)
Interest income		8,018			7,385
Interest expense		(14	)		249
Other income (expense), net		68			(9	)
Total other income, net		8,072			7,625
Loss before income taxes		(11,723	)		(14,173	)
Provision for (benefit from) income taxes		176			(327	)
Net loss from consolidated operations		(11,899	)		(13,846	)
Net loss attributable to noncontrolling interests		369			384
Net loss attributable to Fulgent	$	(11,530	)	$	(13,462	)

Net loss per common share attributable to Fulgent
Basic	$	(0.37	)	$	(0.45	)
Diluted	$	(0.37	)	$	(0.45	)
Weighted-average common shares:
Basic		30,832			29,769
Diluted		30,832			29,769

The accompanying notes are an integral part of these condensed consolidated financial statements.

FULGENT GENETICS, INC.

Condensed Consolidated Statements of Comprehensive Loss

(in thousands)

(unaudited)


	Three Months Ended March 31,
	2025			2024
Net loss from consolidated operations	$	(11,899	)	$	(13,846	)
Other comprehensive income (loss):
Foreign currency translation income (loss)		109			(333	)
Net gain (loss) on available-for-sale debt securities, net of tax		4,624			(2,072	)
Net comprehensive loss from consolidated operations		(7,166	)		(16,251	)
Net loss attributable to noncontrolling interest		369			384
Foreign currency translation (gain) loss attributable to noncontrolling interest		(30	)		98
Comprehensive loss attributable to noncontrolling interest		339			482
Comprehensive loss attributable to Fulgent	$	(6,827	)	$	(15,769	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

FULGENT GENETICS, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands)

(unaudited)


	Fulgent Stockholders’ Equity
	Shares			Amount		Additional Paid-In Capital			Accumulated Other Comprehensive (Loss) Income			Retained Earnings			Fulgent Stockholders’ Equity			Noncontrolling Interest			Total Equity
Balance at December 31, 2024		30,841		$	3	$	543,126		$	(368	)	$	590,467		$	1,133,228		$	(4,069	)	$	1,129,159
Equity-based compensation		—			—		10,550			—			—			10,550			—			10,550
Restricted stock awards		360			—		—			—			—			—			—			—
Common stock withholding for employee tax obligations		(111	)		—		(1,887	)		—			—			(1,887	)		—			(1,887	)
Repurchase of common stock		(469	)		—		(7,886	)		—			—			(7,886	)		—			(7,886	)
Other comprehensive income, net		—			—		—			4,703			—			4,703			30			4,733
Net loss		—			—		—			—			(11,530	)		(11,530	)		(369	)		(11,899	)
Balance at March 31, 2025		30,621		$	3	$	543,903		$	4,335		$	578,937		$	1,127,178		$	(4,408	)	$	1,122,770

The accompanying notes are an integral part of these condensed consolidated financial statements.

FULGENT GENETICS, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands)

(unaudited)


	Fulgent Stockholders’ Equity
	Shares (1)			Amount		Additional Paid-In Capital			Accumulated Other Comprehensive Income (Loss)			Retained Earnings			Fulgent Stockholders’ Equity			Noncontrolling Interest			Total Equity
Balance at December 31, 2023		29,653		$	3	$	501,718		$	1,205		$	633,175		$	1,136,101		$	(2,815	)	$	1,133,286
Equity-based compensation		—			—		11,518			—			—			11,518			—			11,518
Exercise of common stock options		1			—		—			—			—			—			—			—
Restricted stock awards		315			—		—			—			—			—			—			—
Common stock withholding for employee tax obligations		(69	)		—		(1,682	)		—			—			(1,682	)		—			(1,682	)
Repurchase of common stock		(10	)		—		(225	)		—			—			(225	)		—			(225	)
Other comprehensive loss, net		—			—		—			(2,307	)		—			(2,307	)		(98	)		(2,405	)
Net loss		—			—		—			—			(13,462	)		(13,462	)		(384	)		(13,846	)
Balance at March 31, 2024		29,890		$	3	$	511,329		$	(1,102	)	$	619,713		$	1,129,943		$	(3,297	)	$	1,126,646

(1) 185,503 shares of the Company’s common stock were not issued and were held back by the Company as partial security for the indemnification obligations in connection with the business combination of Fulgent Pharma Holdings, Inc., as of March 31, 2024, and December 31, 2023.

The accompanying notes are an integral part of these condensed consolidated financial statements.

FULGENT GENETICS, INC.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)


	Three Months Ended March 31,
	2025			2024
Cash flow from operating activities:
Net loss from consolidated operations	$	(11,899	)	$	(13,846	)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Equity-based compensation		10,550			11,518
Depreciation and amortization		5,919			6,663
Adjustment for credit losses		2,075			(2,497	)
Noncash lease expense		350			1,510
(Gain) loss on disposal of fixed asset		(2	)		183
Amortization of discount of marketable securities		(1,658	)		(1,184	)
Deferred taxes		(133	)		(557	)
Unrecognized tax benefits		137			—
Net realized loss on marketable securities		—			580
Other		21			(12	)
Changes in operating assets and liabilities:
Trade accounts receivable		(4,524	)		1,484
Income tax		1,761			5,154
Other current and long-term assets		804			(24	)
Accounts payable		(658	)		(245	)
Contract liabilities		582			(111	)
Customer deposits		83			4,547
Accrued liabilities and other liabilities		(7,485	)		(4,385	)
Operating lease liabilities		(354	)		(1,512	)
Net cash (used in) provided by operating activities		(4,431	)		7,266
Cash flow from investing activities:
Purchase of marketable securities		—			(195,741	)
Purchases of fixed assets		(4,718	)		(4,056	)
Maturities of marketable securities		32,445			95,450
Proceeds from sale of marketable securities		—			56,903
Proceeds from sale of fixed assets		2			258
Net cash provided by (used in) investing activities		27,729			(47,186	)
Cash flow from financing activities:
Common stock withholding for employee tax obligations		(1,887	)		(1,682	)
Repayment of notes payable		(470	)		(765	)
Principal paid for finance lease		(136	)		(135	)
Repurchase of common stock		(8,679	)		(225	)
Net cash used in financing activities		(11,172	)		(2,807	)
Effect of exchange rate changes on cash and cash equivalents		11			(69	)
Net increase (decrease) in cash, cash equivalents, and restricted cash		12,137			(42,796	)
Cash, cash equivalents, and restricted cash at beginning of period		55,279			97,473
Cash, cash equivalents, and restricted cash at end of period	$	67,416		$	54,677
Supplemental disclosures of cash flow information:
Cash and cash equivalents	$	67,281			54,677
Restricted cash		135			—
Total cash, cash equivalents, and restricted cash	$	67,416		$	54,677
Income taxes paid	$	54			1,307
Interest Paid	$	61			439
Supplemental disclosures of non-cash investing and financing activities:
Purchases of fixed assets in accounts payable	$	2,322			4,739
Operating lease right-of-use assets reduced due to lease modification and termination	$	—			57
Sale of fixed assets in other receivable	$	—			11

The accompanying notes are an integral part of these condensed consolidated financial statements.

FULGENT GENETICS, INC.

Notes to the Condensed Consolidated Financial Statements

(unaudited)

Note 1. Overview and Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. These financial statements include the assets, liabilities, revenues and expenses of all subsidiaries and entities in which the Company has a controlling financial interest or is deemed to be the primary beneficiary. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. The Company uses the equity method to account for its investments in entities that it does not control, but in which it has the ability to exercise significant influence over operating and financial policies. All intercompany accounts and transactions are eliminated from the accompanying condensed consolidated financial statements.

Nature of the Business

Fulgent Genetics, Inc., together with its subsidiaries and affiliated professional corporations, or PCs (collectively referred to as the Company, unless otherwise noted or the context otherwise requires), is a technology-based company with a well-established laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory services and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.

Unaudited Interim Financial Information

The accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company’s audited consolidated financial statements as of and for the fiscal year ended December 31, 2024, which are included in the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on February 28, 2025, or the 2024 Annual Report, and, in the opinion of management, include all adjustments, which are normal and recurring in nature, necessary for a fair presentation of the Company’s financial position and results of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or any other period. The accompanying Condensed Consolidated Balance Sheet as of December 31, 2024, has been derived from the Company’s audited consolidated financial statements at that date but does not include all of the disclosures required by U.S. GAAP. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the 2024 Annual Report, including the notes thereto.

Note 2. Summary of Significant Accounting Policies

See Note 2, Summary of Significant Accounting Policies, to the Company’s Consolidated Financial Statements included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 28, 2025, or the 2024 Annual Report.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. These estimates, judgments and assumptions are based on historical data and experience available at the date of the accompanying condensed consolidated financial statements, as well as various other factors management believes to be reasonable under the circumstances. The Company’s estimates and assumptions may evolve as conditions change. Actual results could differ significantly from these estimates.

On an ongoing basis, management evaluates its estimates, primarily those related to: (i) revenue recognition criteria, (ii) accounts receivable and allowances for credit losses, (iii) the useful lives of fixed assets and intangible assets, (iv) estimates of tax liabilities, (v) valuation of goodwill and indefinite-lived intangible assets at time of acquisition and on a recurring basis, and (vi) valuation of investments.

Trade Accounts Receivable and Allowance for Credit Losses

Trade accounts receivable are stated at the amount the Company expects to collect. The Company maintains an allowance for credit losses for expected uncollectible trade accounts receivable, which is recorded as an offset to trade accounts receivable, and changes in allowance for credit losses are classified as a general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. The Company assesses collectability by reviewing trade accounts receivable on a collective basis where similar risk characteristics exist and on an individual basis when it identifies specific customers that have deterioration in credit quality such that they may no longer share similar risk characteristics with the other receivables. In determining the amount of the allowance for credit losses, the Company uses a loss rate model or probability-of-default and loss given default model. Following the loss rate method, expected credit losses are determined based on an estimated historical loss rate. The probability of default method allows the ability to define a point of default and measure credit losses for receivables that have reached the point of default for purposes of calculating the allowance for credit losses. Loss given default represents the likelihood that a receivable that has reached the point of default will not be collected in full. The Company updates its loss rate and factors annually to incorporate the most recent historical data and adjusts the quantitative portion of the reserve through its qualitative reserve overlay. The Company looks at qualitative factors such as general economic conditions in determining expected credit losses.

A roll-forward of the activity in the Company’s allowance for credit losses for the three months ended March 31, 2025, dollars in thousands, is as follows:


Allowance for credit losses at beginning of year	$	20,458
Current period provision		2,075
Write-downs		(1,643	)
Recoveries of amounts previously charged off		45
Allowance for credit losses as of March 31, 2025	$	20,935

Finite-Lived Intangible Assets

Intangible assets, unless determined to be indefinite-lived, are amortized over their estimated useful lives. The Company amortizes intangible assets on a straight-line basis with definite lives generally over periods ranging from three to 14 years. See Note 14, Goodwill and Intangible Assets, for details of intangible assets.

Impairment of Long-Lived Assets

The Company evaluates the carrying amount of its long-lived assets whenever events or changes in circumstances indicate that the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of an asset and its eventual disposition are less than the carrying amount of the asset.

Goodwill and Indefinite-Lived Intangibles

In-process research & development, or IPR&D, costs are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.

The Company assesses goodwill and indefinite-lived intangibles for impairment on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The Company may choose to bypass a qualitative assessment of impairment for any reporting unit and proceed directly to performing a quantitative assessment. An impairment loss would be recognized for the amount by which the reporting unit’s carrying amount exceeds its fair value.

The Company’s quantitative assessment includes estimating the fair value of each reporting unit and comparing it to its carrying value. The Company estimates the fair value of reporting units using both income-based and market-based valuation methods and typically engages a third-party appraisal firm to assist with the valuation. The estimated fair value for each reporting unit is determined based upon the range of estimated values developed from the income and market-based methods. If the estimated fair value of a reporting unit exceeds its carrying value, the goodwill is not impaired, and no further review is required.

The income-based fair value methodology is based on a reporting unit’s forecasted future cash flows that are discounted to the present value using the reporting unit’s weighted-average cost of capital, or WACC. Under the income-based approach, it requires management’s assumptions and judgments regarding economic conditions in the markets in which the company operates and conditions in the capital markets, many of which are outside of management’s control. The market-based fair value methodology looks at the guideline public company valuation method to determine the prices of comparable public companies and looks at merger and acquisition methods, similar businesses that were sold recently, to estimate the value of the reporting units.

Under the market-based approach, judgment is required in evaluating market multiples and recent transactions.

Fair Value of Financial Instruments

The Company’s financial instruments consist principally of cash and cash equivalents, marketable securities, trade accounts receivable, restricted cash, a redeemable preferred stock investment, preferred stock investments, accounts payable, and accrued liabilities. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short maturities. Fair value of marketable securities, the redeemable preferred stock investment, and the preferred stock investments is disclosed in Note 4, Fair Value Measurements, to the accompanying condensed consolidated financial statements.

Concentrations of Credit Risk, Customers, and Suppliers

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, trade accounts receivable, and marketable securities. As of March 31, 2025, substantially all of the Company’s cash and cash equivalents were deposited in accounts at financial institutions, and amounts typically exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which its cash and cash equivalents are held.

In certain periods, a small number of customers has accounted for a significant portion of the Company’s revenue. For the laboratory services segment, aggregating customers under common control, one customer comprised of $17.6 million, or 24%, of total revenue in the three months ended March 31, 2025, and $12.6 million, or 20%, of the Company’s revenue in the three months ended March 31, 2024. The same customer comprised 21% of total accounts receivable, net, as of March 31, 2025, and 15% of total accounts receivable, net, as of December 31, 2024. For the therapeutic development segment, the Company does not have customers or revenue as it does not have any commercialized or approved drug candidates.

The Company’s therapeutic development business relies on ANP Technologies, Inc., or ANP, for certain laboratory services, equipment, tools, and drug intermediates in connection with research and development efforts. The Company also relies on a limited number of suppliers for certain laboratory substances used in the chemical reactions incorporated into its processes, referred to as reagents, as well as for the sequencers and various other equipment and materials it uses in its laboratory operations. In particular, the Company relies on a sole supplier for the next generation sequencers and associated reagents it uses to perform its genetic tests and as the sole provider of maintenance and repair services for these sequencers. The Company’s laboratory operations would be interrupted if it encountered delays or difficulties securing these reagents, sequencers, other equipment or materials or maintenance and repair services, which could occur for a variety of reasons, including if the Company needs a replacement or temporary substitute for any of its limited or sole suppliers and is not able to locate and make arrangements with an acceptable replacement or temporary substitute. The Company’s development efforts could also be delayed or interrupted if it is unable to procure items needed for its therapeutic development activities. The Company believes there are currently only a few other manufacturers that are capable of supplying and servicing some of the equipment and other materials necessary for its laboratory operations, including sequencers and various associated reagents.

Reportable Segment and Geographic Information

Reporting segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, in making decisions regarding resource allocation and assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. The Company reports its business in two segments, a laboratory services business and a therapeutic development business. For further financial information about these segments, including information for each of the periods presented regarding revenue, operating income (loss), and other important information, see Note 7, Reportable Segment and Geographic Information, to the accompanying condensed consolidated financial statements.

Foreign Currency Translation and Foreign Currency Transactions

The Company translates the assets and liabilities of its non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recognized in foreign currency translation gain (loss) included in the accompanying Condensed Consolidated Statements of Comprehensive Loss.

The Company and its subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, and reagents and supplies, property, and nonmonetary assets and liabilities at historical rates. Gains and losses from these measurements are included in other income, net, in the accompanying Condensed Consolidated Statements of Operations. Losses from foreign currency exchange were not significant for the three months ended March 31, 2025, and 2024.

Income Taxes

The effective tax rate used for interim periods is the estimated annual effective consolidated tax rate, based on the current estimate of full year results, except that taxes related to specific events, if any, are recorded in the interim period in which they occur. The annual effective tax rate is based upon several significant estimates and judgments, including the estimated annual pre-tax income (loss) of the Company in each tax jurisdiction in which it operates, and the development of tax planning strategies during the year. In addition, the Company’s tax expense can be impacted by changes in tax rates or laws and other factors that cannot be predicted with certainty. As such, there can be significant volatility in interim tax provisions.

Comprehensive Loss

Comprehensive loss is comprised of net loss and other comprehensive loss. Other comprehensive loss consists of net unrealized gain or loss on available-for-sale debt securities, net of tax, and foreign currency translation adjustments from the Company’s subsidiaries not using the U.S. dollar as their functional currency. There were no reclassifications from other comprehensive loss to net loss in the three months ended March 31, 2025. Reclassifications from other comprehensive loss to net loss were $0.6 million in the three months ended March 31, 2024. The tax effect related to net unrealized gain or loss on the available-for-sale debt securities was zero in the three months ended March 31, 2025, and 2024, due to the valuation allowance in the current period that precludes the Company from recognizing the deferred tax benefit.

Disaggregation of Revenue

The Company classifies its customers into three payor types: (i) Institutional, including hospitals, medical institutions, other laboratories, governmental bodies, municipalities, and large corporations, (ii) Insurance, or (iii) Patients who pay directly, as the Company believes this best depicts how the nature, amount, timing, and uncertainty of its revenue and cash flows are affected by economic factors. The following table summarizes revenue from contracts with customers by payor type for the three months ended March 31, 2025, and 2024:


	Three Months Ended March 31,
	2025		2024
	(in thousands)
Revenue by payor
Institutional	$	41,324	$	33,604
Insurance		30,744		30,043
Patients		1,395		838
Total revenue	$	73,463	$	64,485

During the three months ended March 31, 2024, the Company experienced a change in estimate related to variable consideration, leading to the recognition of $1.2 million variable consideration, that related to COVID-19 test services completed in the prior periods due to collection efforts. This was included as revenue from insurance in the table above. There was zero such variable consideration recognized in the three months ended March 31, 2025. The Company estimates variable consideration using the expected value method. Any changes in variable consideration estimates that affect transactions are accounted for on a cumulative catch-up basis.

Contract Balances

Receivables from contracts with customers - Receivables from contracts with customers are included within trade accounts receivable on the Condensed Consolidated Balance Sheets. Receivables from Insurance and Institutional customers represented 41% and 59%, respectively, as of March 31, 2025, and 44% and 56%, respectively, as of December 31, 2024.

Contract assets and liabilities - Contract assets from contracts with customers associated with contract execution and certain costs to fulfill a contract are included in other current assets in the accompanying Condensed Consolidated Balance Sheets. Contract liabilities are recorded when the Company receives payment prior to completing its obligation to transfer goods or services to a customer.

Contract liabilities are included in the Condensed Consolidated Balance Sheets. Revenues of $0.1 million and $0.9 million were recognized for the three months ended March 31, 2025, and 2024, respectively, related to contract liabilities at the beginning of the respective periods.

Prior Period Reclassifications

Certain amounts reported in the prior period have been reclassified to conform with the current period presentation. In the Condensed Consolidated Statements of Cash Flow, the Company has separated income taxes from its previous inclusion in other current and long-term assets and separated customer deposits, and contract liabilities from its previous inclusion in accrued liabilities and other liabilities. In the Condensed Consolidated Statements of Operations, the Company has also separated interest income, and interest expenses from its previous inclusion in other income (expense), net. In Note 6. Other Significant Balance Sheet Accounts, the Company has consolidated accrued legal liabilities with other accrued liabilities.

Recent Accounting Pronouncements

The Company evaluates all Accounting Standards Updates, or ASUs, issued by the Financial Accounting Standards Board, or FASB, for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s condensed consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures. This update requires more detailed information on certain income tax disclosures including the income tax rate reconciliation and income taxes paid. Amendments in this update are effective for annual periods beginning December 15, 2024, for public entities, and early adoption is permitted. This update is intended to result in enhanced income tax disclosures, and the Company does not expect any impact to income tax expense.

In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This update requires disclosure in the notes to financial statements, of specified information about certain costs and expenses. Amendments in this update are effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impacts of this amendment on its consolidated financial statements and related disclosure.

The Company does not expect that any other recently issued accounting guidance will have a significant effect on its condensed consolidated financial statements.

Note 3. Equity and Debt Securities

The Company’s equity and debt securities consisted of the following:


	March 31, 2025
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Equity securities
Long-term
Preferred stock of privately-held companies	$	24,927		$	—	$	—		$	24,927
Total equity securities		24,927			—		—			24,927
Available-for-sale debt securities
Short-term
U.S. agency debt securities		115,401			90		(67	)		115,424
U.S. government debt securities		77,451			102		(38	)		77,515
U.S. treasury bills		34,812			2		(2	)		34,812
Corporate debt securities		22,736			37		(90	)		22,683
Municipal bonds		2,608			1		(3	)		2,606
Money market accounts		58,539			—		—			58,539
Less: Cash equivalents		(58,539	)		—		—			(58,539	)
Total debt securities due within 1 year		253,008			232		(200	)		253,040
After 1 year through 5 years
U.S. government debt securities		359,594			2,243		(474	)		361,363
U.S. agency debt securities		90,129			146		(560	)		89,715
Corporate debt securities		40,570			195		(34	)		40,731
Municipal bonds		1,820			2		(4	)		1,818
Yankee debt securities		501			—		(17	)		484
Total debt securities due after 1 year through 5 years		492,614			2,586		(1,089	)		494,111
Total available-for-sale debt securities		745,622			2,818		(1,289	)		747,151
Total equity and debt securities	$	770,549		$	2,818	$	(1,289	)	$	772,078


	December 31, 2024
	Amortized Cost Basis			Unrealized Gains			Unrealized Losses			Aggregate Fair Value
	(in thousands)
Equity securities
Long-term
Preferred stock of privately-held companies	$	24,927		$	—		$	—		$	24,927
Total equity securities		24,927			—			—			24,927
Available-for-sale debt securities
Short-term
U.S. government debt securities		75,054			136			(25	)		75,165
U.S. agency debt securities		65,490			72			(23	)		65,539
U.S. treasury bills		44,366			19			(2	)		44,383
Corporate debt securities		19,177			12			(50	)		19,139
Municipal bonds		3,719			1			(7	)		3,713
Money market accounts		19,720			—			—			19,720
Less: Cash equivalents		(24,696	)		(1	)		—			(24,697	)
Total debt securities due within 1 year		202,830			239			(107	)		202,962
After 1 year through 5 years
U.S. government debt securities		379,060			565			(2,283	)		377,342
U.S. agency debt securities		144,398			57			(1,507	)		142,948
Corporate debt securities		47,801			114			(150	)		47,765
Municipal bonds		1,820			2			(4	)		1,818
Yankee debt securities		501			—			(23	)		478
Total debt securities due after 1 year through 5 years		573,580			738			(3,967	)		570,351
Total available-for-sale debt securities		776,410			977			(4,074	)		773,313
Total equity and debt securities	$	801,337		$	977		$	(4,074	)	$	798,240

Gross unrealized losses on the Company’s equity and debt securities were $1.3 million and $4.1 million as of March 31, 2025, and December 31, 2024, respectively. There were no sales of available-for-sale securities or realized gain or loss for the three months ended March 31, 2025. Proceeds from sale of available-for-sale securities were $56.9 million for the three months ended March 31, 2024. Gross realized losses on the Company’s available-for-sale securities were $0.6 million for the three months ended March 31, 2024, and the gross realized income was insignificant for the three months ended March 31, 2024. The cost of any marketable securities sold is based on the specific-identification method. The Company did not recognize any credit losses for its marketable available-for-sale debt securities during the three months ended March 31, 2025, and 2024.

Note 4. Fair Value Measurements

The authoritative guidance on fair value measurements establishes a framework with respect to measuring assets and liabilities at fair value on a recurring basis and non-recurring basis. Under the framework, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as of the measurement date. The framework also establishes a three-tier hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability and are developed based on the best information available in the circumstances. The hierarchy consists of the following three levels:


Level 1:	Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.
Level 2:	Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
Level 3:	Inputs are unobservable for the asset or liability.

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the above three-tier fair value hierarchy:


	March 31, 2025
	Total		Level 1		Level 2		Level 3
	(in thousands)
Equity securities, debt securities and cash equivalents
U.S. government debt securities	$	438,878	$	—	$	438,878	$	—
U.S. agency debt securities		205,139		—		205,139		—
Corporate debt securities		63,414		—		63,414		—
Money market accounts		58,539		58,539		—		—
U.S. treasury bills		34,812		34,812		—		—
Preferred stock of privately-held companies		24,927		—		—		24,927
Municipal bonds		4,424		—		4,424		—
Yankee debt securities		484		—		484		—
Total equity securities, debt securities and cash equivalents	$	830,617	$	93,351	$	712,339	$	24,927


	December 31, 2024
	Total		Level 1		Level 2		Level 3
	(in thousands)
Equity securities, debt securities and cash equivalents
U.S. government debt securities	$	452,507	$	—	$	452,507	$	—
U.S. agency debt securities		208,487		—		208,487		—
Corporate debt securities		66,904		—		66,904		—
U.S. treasury bills		44,383		44,383		—		—
Preferred stock of privately-held companies		24,927		—		—		24,927
Money market accounts		19,720		19,720		—		—
Municipal bonds		5,531		—		5,531		—
Yankee debt securities		478		—		478		—
Total equity securities, debt securities and cash equivalents	$	822,937	$	64,103	$	733,907	$	24,927

The Company’s Level 1 assets include U.S. treasury bills and money market instruments and are valued based upon observable market prices. Level 2 assets consist of U.S. government and U.S. agency debt securities, municipal bonds, corporate debt securities and Yankee debt securities. Level 2 securities are valued based upon observable inputs that include reported trades, broker/dealer quotes, bids and offers. As of March 31, 2025, and December 31, 2024, the Company had preferred stock of two privately-held companies, which were included in other long-term assets in the accompanying Condensed Consolidated Balance Sheets that were measured using unobservable (Level 3) inputs. For the value of the investment in private equity securities, the Company elected to measure them at cost minus impairment, as the preferred stock of the privately-held companies did not have a readily determinable fair value, and no impairment loss was recorded as of March 31, 2025.

There were no transfers between fair value measurement levels during the three months ended March 31, 2025, and 2024.

Note 5. Fixed Assets

Major classes of fixed assets consisted of the following:


	Useful Lives	March 31, 2025			December 31, 2024
		(in thousands)
Medical lab equipment	5 months to 13 Years	$	57,657		$	57,541
Building improvements	6 months to 39 Years		27,943			27,924
Building	25 to 39 Years		21,689			21,689
Computer hardware	1 to 5 Years		9,998			7,328
Computer software	1 to 10 Years		6,648			7,214
Aircraft	7 Years		6,400			6,400
Furniture and fixtures	1 to 11 Years		4,110			4,109
Leasehold improvements	Shorter of lease term or estimated useful life		4,308			3,323
Land improvements	5 to 15 Years		938			904
Automobile	3 to 8 Years		616			581
General equipment	5 Years		108			108
Land			17,347			17,347
Assets not yet placed in service			4,183			2,792
Total			161,945			157,260
Less: Accumulated depreciation			(54,868	)		(51,711	)
Fixed assets, net		$	107,077		$	105,549

Depreciation expense on fixed assets totaled $3.8 million and $4.6 million for the three months ended March 31, 2025, and 2024, respectively.

Note 6. Other Significant Balance Sheet Accounts

Other current assets consisted of the following:


	March 31, 2025		December 31, 2024
	(in thousands)
Reagents and supplies	$	8,620	$	8,384
Marketable securities interest receivable		6,427		6,241
Prepaid expenses		5,742		6,629
Prepaid income taxes		1,661		3,422
Other receivable		2,535		1,768
Total	$	24,985	$	26,444

Accrued liabilities consisted of the following:


	March 31, 2025		December 31, 2024
	(in thousands)
Payroll liabilities	$	4,963	$	8,210
Vacation accrual		4,573		4,088
Accrued bonus and commission		1,553		5,803
Operating lease liabilities - short term		1,330		1,443
Other accrued liabilities		4,270		4,735
Total	$	16,689	$	24,279

Other accrued liabilities as of December 31, 2024, included $1.0 million in connection with the SEC investigation, as further described in Note 8, Debt, Commitments, and Contingencies. This amount has now been released after the SEC investigation was closed without any enforcement action recommended. Other accrued liabilities also included short-term finance lease liabilities, health insurance liabilities, and third-party billing services.

Other long-term liabilities consisted of the following:


	March 31, 2025		December 31, 2024
	(in thousands)
Operating lease liabilities, long term	$	3,893	$	4,120
Notes payable, long term		1,958		2,493
Other long-term liabilities		271		360
Total	$	6,122	$	6,973

Note 7. Reportable Segment and Geographic Information

The Company has two distinct reportable segments. The laboratory services operating segment offers technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians who specialize in pathology and oncology. The therapeutic development operating segment is a pharmaceutical research and development entity.

The Company’s Chief Executive Officer serves as its Chief Operating Decision Maker, or CODM. The CODM oversees the Company’s operations and evaluates financial data for its two operating segments separately to make resource allocation decisions. The financial information regularly provided to the CODM includes various performance metrics by reporting segment, such as gross profit, operating income or loss, income or loss before income taxes, net income or loss from consolidated operations, and net income or loss attributable to Fulgent, all presented in accordance with U.S. GAAP. Additionally, the CODM receives these metrics on a non-GAAP basis, which excludes the impact of equity-based compensation expenses, goodwill impairment losses, amortization of intangible assets, and restructuring costs, if applicable. Although multiple financial metrics are provided, the CODM primarily relies on adjusted operating income or loss to evaluate segment performance and allocate resources. The balance sheet is presented on a consolidated basis, as the CODM does not use asset or liability information, including fixed assets, to assess segment performance. As a result, segment asset and liability details are not disclosed.

There is no inter-segment allocation of interest expense and income taxes. There is no inter-segment revenue and operating income or loss. The Company did not allocate income tax by segment. Information regarding the Company’s operations and assets for its reporting segments as well as geographic information are as follows, all dollars are in thousands:


	Laboratory Services			Therapeutic Development			Total
Three Months Ended March 31, 2025
Revenue	$	73,463		$	—		$	73,463
Less:
Adjusted cost of revenue		43,337			—			43,337
Adjusted research and development		4,931			3,990			8,921
Adjusted selling and marketing		7,575			—			7,575
Adjusted general and administrative		20,624			261			20,885
Total adjusted operating loss	$	(3,004	)	$	(4,251	)	$	(7,255	)


	Laboratory Services			Therapeutic Development			Total
Three Months Ended March 31, 2024
Revenue	$	64,485		$	—		$	64,485
Less:
Adjusted cost of revenue		40,372			—			40,372
Adjusted research and development		4,200			3,390			7,590
Adjusted selling and marketing		7,939			—			7,939
Adjusted general and administrative		16,700			174			16,874
Total adjusted operating loss	$	(4,726	)	$	(3,564	)	$	(8,290	)


	Three Months Ended March 31,
	2025			2024
Reconciliation of “adjusted operating loss” to “loss before income taxes”
Adjusted operating loss	$	(7,255	)	$	(8,290	)
Less (add):
Equity-based compensation		10,550			11,518
Amortization of intangible assets		1,990			1,990
Interest income		(8,018	)		(7,385	)
Interest expense		14			(249	)
Other income, net		(68	)		9
Total loss before income taxes	$	(11,723	)	$	(14,173	)

Significant items by segment excluded from the adjusted operating (loss) income:


	Three Months Ended March 31,
	2025		2024
Equity-based compensation
Laboratory services	$	8,532	$	10,037
Therapeutic development		2,018		1,481
Total	$	10,550	$	11,518

Revenue by segment:


	Three Months Ended March 31,
	2025		2024
Revenue
Laboratory services:
Precision diagnostics	$	44,097	$	37,446
Anatomic pathology		25,300		23,107
BioPharma services		4,066		2,656
COVID-19		—		1,276
Total laboratory services		73,463		64,485
Therapeutic development		—		—
Total	$	73,463	$	64,485

Depreciation and amortization by segment:


	Three Months Ended March 31,
	2025		2024
Depreciation and amortization:
Laboratory services	$	5,755	$	6,489
Therapeutic development		164		174
Total	$	5,919	$	6,663

Interest income and expense by segment:


	Three Months Ended March 31,
	2025			2024
Interest income and expense
Laboratory services
Interest income	$	8,018		$	7,385
Interest expense		(14	)		249
Therapeutic development
Interest income		—			—
Interest expense		—			—
Total	$	8,004		$	7,634

Total assets by segment:


	March 31, 2025		December 31, 2024
Assets:
Laboratory services	$	1,116,841	$	1,131,117
Therapeutic development		88,903		88,847
Total	$	1,205,744	$	1,219,964

Geographic distribution of revenue:


	Three Months Ended March 31,
	2025		2024
Revenue
United States	$	67,826	$	57,850
Foreign
China		2,611		4,104
Other countries		3,026		2,531
Total foreign		5,637		6,635
Total	$	73,463	$	64,485

Geographic distribution of property, plant and equipment, net:


	March 31, 2025		December 31, 2024
Fixed assets
United States	$	100,617	$	98,992
Foreign
China		4,704		4,616
Other countries		1,756		1,941
Total foreign		6,460		6,557
Total	$	107,077	$	105,549

Note 8. Debt, Commitments, and Contingencies

Debt

Notes payable as of March 31, 2025, consisted of $2.4 million of notes payable related to an installment sale contract the Company entered in February 2022 for a building. The notes payable related to the installment sale are due in February 2030, and carry an interest rate of 1.08%. The current portion and noncurrent portion are $0.5 million and $2.0 million, respectively, and the noncurrent portion is included in the other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets. The interest expenses for the three months ended March 31, 2025, and 2024, were not significant.

Operating and Finance Leases

See Note 9, Leases, for further information.

Contingencies

From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business.

As previously disclosed in the Company’s periodic reports filed pursuant to the Securities Exchange Act of 1934, as amended, or the Exchange Act, the Company has received a Civil Investigative Demand, or CID, issued by the U.S. Department of Justice, or the DOJ, pursuant to the False Claims Act related to its investigation of allegations of medically unnecessary laboratory testing, improper billing for laboratory testing, and remuneration received or provided in violation of the Anti-Kickback Statute and the Stark Law. Among other things, this CID requests information and records relating to certain of the Company’s customers named in this CID.

Similar to other laboratories in the industry, the Company has been subject to an audit by the U.S. Health Resources and Services Administration, or HRSA, with respect to its reimbursement for COVID-19 tests furnished to patients believed to be uninsured. The Company recorded approximately $548.9 million of reimbursements from HRSA under the Uninsured Program during the years ended December 31, 2022, 2021, and 2020.

There is uncertainty with respect to the methodology HRSA will use in its audit and whether and how HRSA will extrapolate audit results. The Company has provided HRSA’s auditors with requested information in connection with its audit in an effort to resolve any issues related to its audit, including any reimbursed amounts that may need to be returned to HRSA. The Company has also received a CID issued by the DOJ pursuant to the False Claims Act related to the DOJ’s investigation as to whether the Company submitted or caused to be submitted false claims to the Uninsured Program.

The Company is fully cooperating with the DOJ in connection with the CIDs that it has received. The Company cannot currently predict when these CIDs and HRSA audit matters will be resolved, the reasonable or likely outcome of these matters, or their potential impact, which may materially and adversely affect the Company’s business, prospects, and financial condition. These matters are not formal claims, and discussions and investigations remain ongoing. As such, the Company cannot reasonably estimate the loss or range of loss, if any, that may result from any material government investigations, audits, and reviews in which it is currently involved, given the inherent difficulty in predicting regulatory action, fines and penalties, if any, and the various remedies and levels of judicial review available to the Company in the event of an adverse finding. As a result, the Company has not recorded any liability related to these CIDs or audit matters.

In addition, and as previously disclosed, the SEC was conducting a non-public formal investigation, which related to (i) the matters raised in the requests for the CID regarding allegations of medically unnecessary laboratory testing, improper billing for laboratory testing, and remuneration received or provided in violation of the Anti-Kickback Statute and the Stark Law and (ii) the Company’s Exchange Act reports filed for 2018 through 2020. On May 6, 2024, the SEC staff advised the Company that the SEC staff made a preliminary determination to recommend that the SEC file an enforcement action against the Company based on a corporate negligence theory, which, if authorized, would have alleged violations of the Securities and Exchange Act. In April 2025, the SEC advised the Company that it had concluded this investigation, with no enforcement action recommended. The Company previously recorded a $1.0 million potential liability with respect to this matter and is no longer recording any potential liability in connection with this matter.

Note 9. Leases

Lessee

The Company is party as a lessee to various non-cancelable operating leases with varying terms through March 2034 primarily for laboratory and office space and equipment. The Company has options to renew some of these leases after their expirations. On a lease-by-lease basis, the Company considers such options, which may be elected at the Company’s sole discretion, in determining the lease term. The Company also has various finance leases for lab equipment with varying terms through December 2026, of which, some were acquired in business combinations. The Company does not have any leases with variable lease payments. The Company’s operating lease agreements do not contain any residual value guarantees, material restrictive covenants, bargain purchase options, or asset retirement obligations.

The Company’s headquarters are located in El Monte, California, which is comprised of various corporate offices and a laboratory certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, accredited by the College of American Pathologists, or CAP, and licensed by the State of California Department of Public Health. Other CLIA-certified laboratories are located in Coppell, Texas; Needham, Massachusetts; Phoenix, Arizona; and Alpharetta, Georgia. The Company is also in the process of obtaining NATA accreditation in Dulwich, Australia.

The operating and finance lease right-of-use asset, short-term lease liabilities, and long-term lease liabilities as of March 31, 2025, and December 31, 2024, were as follows:


	March 31, 2025		December 31, 2024
	(in thousands)
Operating lease ROU asset, net	$	5,058	$	5,395
Operating lease liabilities, short term	$	1,330	$	1,443
Operating lease liabilities, long term	$	3,893	$	4,120
Finance lease ROU asset, net	$	640	$	771
Finance lease liabilities, short term	$	351	$	398
Finance lease liabilities, long term	$	271	$	360

The following was operating and finance lease expense:


	Three Months Ended March 31,
	2025		2024
	(in thousands)
Operating lease cost	$	435	$	1,629
Finance lease cost:
Amortization of ROU assets		132		137
Interest on lease liabilities		6		12
Short-term lease cost		561		316
Total lease cost	$	1,134	$	2,094

Supplemental information related to leases was the following:


	March 31, 2025
Weighted-average remaining lease term, operating leases	5.91 years
Weighted-average discount rate, operating leases		5.33	%
Weighted-average remaining lease term, finance lease	1.75 years
Weighted-average discount rate, finance lease		3.21	%

The following is a maturity analysis of operating and finance lease liabilities using undiscounted cash flows on an annual basis with renewal periods included:


	Operating Leases			Finance Lease
	(in thousands)
Year ending December 31,
2025 (remaining 9 months)	$	1,275		$	275
2026		1,120			366
2027		1,014			—
2028		487			—
2029		504			—
2030		510			—
Thereafter		1,335			—
Total lease payments		6,245			641
Less imputed interest		(1,022	)		(19	)
Total	$	5,223		$	622

Lessor

The Company previously leased out space in buildings it owns to third-party tenants under noncancelable operating leases. As of March 31, 2025, there were no noncancelable operating leases remaining. Lease income primarily represents fixed lease payments from tenants recognized on a straight-line basis over the applicable lease term. Variable lease income represents tenant payments for real estate taxes, insurance, and maintenance.

The lease income was included in other income, net, in the accompanying Condensed Consolidated Statements of Operations, and the lease income was zero for the three months ended March 31, 2025, and not significant for the three months ended March 31, 2024. There are no future lease payments from tenants expected, as there were no remaining noncancelable operating leases as of March 31, 2025.

Note 10. Equity-Based Compensation

The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying Condensed Consolidated Statements of Operations as follows:


	Three Months Ended March 31,
	2025		2024
	(in thousands)
Cost of revenue	$	1,780	$	2,009
Research and development		3,474		3,844
Selling and marketing		890		1,050
General and administrative		4,406		4,615
Total	$	10,550	$	11,518

Note 11. Income Taxes

The Company recorded consolidated provision for (benefit from) income taxes of $0.2 million for the three months ended March 31, 2025, compared to ($0.3) million for the three months ended March 31, 2024. The Company’s effective tax rate was (2%) for the three months ended March 31, 2025, compared to 2% for the three months ended March 31, 2024. The change in the effective tax rate compared to prior periods is due to the valuation allowance in the current period that precludes the Company from recognizing the benefit from net operating losses.

The Company is under examination by certain tax authorities for the 2020 to 2021 tax years. While the timing of the conclusion of the examination is uncertain, the Company believes that adequate amounts have been reserved for adjustments that may result. During 2025, the statutes of limitations will lapse on the Company’s 2021 federal tax year and certain 2020 and 2021 state tax years. The Company does not believe the federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next 12 months.

The Company received $1.7 million and $6.2 million in income tax refunds in the three months ended March 31, 2025, and 2024, respectively. The income tax refunds received were not netted in the income tax paid amounts included in the supplemental disclosure in the accompanying Condensed Consolidated Statements of Cash Flows.

Note 12. Loss per Share

The following table presents the calculation of basic and diluted loss per share for the three months ended March 31, 2025, and 2024:


	Three Months Ended March 31,
	2025			2024
	(in thousands)
Net loss attributable to Fulgent	$	(11,530	)	$	(13,462	)

Weighted-average common shares - outstanding, basic		30,832			29,769
Weighted-average common shares - outstanding, diluted		30,832			29,769

Loss per share:
Basic	$	(0.37	)	$	(0.45	)
Diluted	$	(0.37	)	$	(0.45	)

The following securities have been excluded from the calculation of diluted loss per share because their effect would have been anti-dilutive:


	Three Months Ended March 31,
	2025		2024
	(in thousands)
Stock options		95		222
Restricted stock units		2,340		2,199
Contingently issuable shares		—		186

In the three months ended March 31, 2025, and 2024, the Company had outstanding stock options and restricted stock units that were excluded from the weighted-average share calculation for continuing operations due to the Company’s net loss positions. In the three months ended March 31, 2024, the Company also had contingently issuable shares for shares held back in connection with the business combination of Fulgent Pharma, or Pharma Hold Back Shares. In May 2024, the Company released the remaining Pharma Hold Back Shares such that no shares remain contingently issuable in connection with the business combination of Fulgent Pharma.

Note 13. Related Party

Ming Hsieh, the Chief Executive Officer and Chairperson of the Board of Directors, is on the board of directors and an approximately 20% owner of ANP, with which the Company entered into certain drug-related licensing and development service agreements. The Chief Executive Officer of Fulgent Pharma, Ray Yin, is the Founder, President and Chief Technology Officer of ANP. The Company incurred $0.4 million and $0.7 million related to the licensing and development services in the three months ended March 31, 2025, and 2024, respectively. As of March 31, 2025, and December 31, 2024, the Company owed $0.2 million to ANP in connection with these relationships. The Company also entered into an employee service agreement with ANP in April 2023 and recognized an insignificant amount and $0.1 million in the three months ended March 31, 2025, and 2024, respectively. Insignificant amounts were owed to the Company by ANP in connection with the employee service agreement as of March 31, 2025, and December 31, 2024.

Note 14. Goodwill and Intangible Assets

There was no change in the carrying amount in the three months ended March 31, 2025. Goodwill as of March 31, 2025, and December 31, 2024, was $22.1 million, all of which was related to the therapeutic development business.

The Company has identified its laboratory services business and its therapeutic development business as its two operating segments, and the Company determined that the operating segments represented the two reporting units.

The Company tests for goodwill impairment at the reporting unit level on December 31st of each year and more frequently if events or circumstances indicate a potential impairment.

Therapeutic Development

Based upon the results of the quantitative assessments the Company performed as of December 31, 2024, the Company concluded that the fair values of the therapeutic development reporting unit and the IPR&D asset at December 31, 2024, were greater than the carrying values and that there was no impairment. There have been no significant changes in the three months ended March 31, 2025.

There can be no assurance that the estimates and assumptions management made for the purposes of the goodwill or IPR&D impairment analysis will prove to be accurate predictions of future performance. It is possible that the conclusions regarding impairment or recoverability of goodwill or intangible assets could change in future periods. Management will continue to monitor the therapeutic development reporting unit. For all IPR&D projects, there are major risks and uncertainties associated with the timely and successful completion of development and commercialization of these drug candidates, including the ability to confirm their efficacy based on data from clinical trials, the ability to obtain necessary regulatory approvals, and the ability to successfully complete these tasks within budgeted costs. The Company is not able to market a human therapeutic without obtaining regulatory approvals, and such approvals require completing clinical trials that demonstrate a drug candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from insurance payors, including government healthcare programs and private insurance plans, impact the revenues a product can generate. Consequently, the eventual realized value, if any, of these acquired IPR&D projects may vary from their estimated fair values.

Summaries of intangible assets balances as of March 31, 2025, and December 31, 2024, were as follows:


	Weighted-Average Amortization Period	March 31, 2025			December 31, 2024
		(in thousands)
Laboratory Services
Customer Relationships	13 Years	$	83,094		$	83,088
Less: accumulated amortization			(20,712	)		(19,079	)
Customer relationships, net			62,382			64,009

Royalty-free technology	10 Years		5,099			5,069
Less: accumulated amortization			(1,997	)		(1,859	)
Royalty-free technology, net			3,102			3,210

Trade name	8 Years		3,790			3,790
Less: accumulated amortization			(1,525	)		(1,401	)
Trade name, net			2,265			2,389

Laboratory information system platform	5 Years		1,860			1,860
Less: accumulated amortization			(1,364	)		(1,271	)
Laboratory information system platform, net			496			589

In-place lease intangible assets	5 Years		360			360
Less: accumulated amortization			(203	)		(186	)
In-place lease intangible assets, net			157			174

Purchased patent	10 Years		28			27
Less: accumulated amortization			(11	)		(10	)
Purchased patent, net			17			17
Total			68,419			70,388

Therapeutic Development
In-process research & development	n/a		64,590			64,590
Total			64,590			64,590
Total intangible assets, net		$	133,009		$	134,978

Acquisition-related intangibles included in the above tables are generally finite-lived and are carried at cost less accumulated amortization, except for IPR&D, which is related to the acquisition of Fulgent Pharma in 2022 and has an indefinite life until research and development efforts are completed or abandoned. All other finite-lived acquisition-related intangibles related to the business combinations are amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized.

Amortization of intangible assets was $2.0 million for each of the three months ended March 31, 2025, and 2024.

Based on the carrying value of intangible assets recorded as of March 31, 2025, and assuming no subsequent impairment of the underlying assets, the annual amortization expense for intangible assets is expected to be as follows:


	Amounts
	(in thousands)
Year ending December 31,
2025 (remaining 9 months)	$	5,970
2026		7,658
2027		7,198
2028		7,164
2029		6,907
2030		6,778
Thereafter		26,744
Total	$	68,419

Note 15. Stock Repurchase Program

In March 2022, the Company’s Board of Directors authorized a $250.0 million stock repurchase program. Under the stock repurchase program, the Company may repurchase shares from time to time in the open market or in privately negotiated transactions. The stock repurchase program has no expiration from the date of authorization.

During the three months ended March 31, 2025, the Company repurchased 0.5 million shares of its common stock at an aggregate cost of $7.9 million, under the stock repurchase program. As of March 31, 2025, an additional $0.8 million was paid for 47,000 shares of its common stock, however the transaction was not settled until early April 2025. During the three months ended March 31, 2024, the Company repurchased 10,000 shares of its common stock at an aggregate cost of $0.2 million. As of March 31, 2025, total of approximately $141.8 million remained available for future repurchases of its common stock under the stock repurchase program.

Note 16. Retirement Plans

The Company offers a 401(k) retirement savings plan, or the 401(k) Plan, for its employees, including its executive officers, who satisfy certain eligibility requirements. The Internal Revenue Code of 1986, as amended, allows eligible employees to defer a portion of their compensation, within prescribed limits, on a pre-tax basis through contributions to the 401(k) Plan. The Company matches contributions to the 401(k) Plan based on the amount of salary deferral contributions the participant makes to the 401(k) Plan. The Company will match up to 4% of an employee’s compensation that the employee contributes to their 401(k) Plan account. Total Company matching contributions to the 401(k) Plan were $1.2 million and $1.0 million for the three months ended March 31, 2025, and 2024, respectively.

Note 17. Subsequent Events

Stock Repurchase Program

From April 1, 2025, through May 2, 2025, the Company repurchased 0.1 million shares of its common stock for an aggregate cost of $2.2 million at an average price of $16.93 per share under the stock repurchase program approved in March 2022. See Note 15, Stock Repurchase Program. As of May 2, 2025, a total of $139.6 million remained available for future repurchases of its common stock under the stock repurchase program.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read together with our condensed consolidated financial statements and related notes included in this report. Additionally, pursuant to Instruction 2 to paragraph (b) of Item 303 of Regulation S-K promulgated by the U.S. Securities and Exchange Commission, or SEC, in preparing this discussion and analysis, we presume that readers have access to and have read the discussion and analysis of our financial condition and results of operations included in our annual report on Form 10-K for our fiscal year ended December 31, 2024, filed with the SEC on February 28, 2025, or the 2024 Annual Report. As used in this discussion and analysis and elsewhere in this report, unless the context otherwise requires, the terms “Fulgent,” the “Company,” “we,” “us” and “our” refer to Fulgent Genetics, Inc. and its consolidated subsidiaries.

Forward-Looking Statements

The following discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements are statements other than historical facts and relate to future events or circumstances or our future performance, and they are based on our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. The forward-looking statements in this discussion and analysis include statements about, among other things, our future financial and operating performance, our future cash flows and liquidity and our growth strategies, the development of our drug candidates, as well as anticipated trends in our business and industry. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, those described under “Item 1A. Risk Factors” in Part I of the 2024 Annual Report. Moreover, we operate in a competitive and rapidly evolving industry and new risks emerge from time to time. It is not possible for us to predict all of the risks we may face, nor can we assess the impact of all factors on our business or the extent to which any factor or combination of factors could cause actual results to differ from our expectations. In light of these risks and uncertainties, the forward-looking events and circumstances described in this discussion and analysis may not occur, and actual results could differ materially and adversely from those described in or implied by any forward-looking statements we make. Although we have based our forward-looking statements on assumptions and expectations we believe are reasonable, we cannot guarantee future results, levels of activity, performance or achievements or other future events. As a result, forward-looking statements should not be relied on or viewed as predictions of future events, and this discussion and analysis should be read with the understanding that actual future results, levels of activity, performance and achievements may be materially different than our current expectations. The forward-looking statements in this discussion and analysis speak only as of the date of this report, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.

Overview

We are a technology-based company with a well-established laboratory services business and a therapeutic development business. Our laboratory services business includes technical laboratory services and testing services and professional interpretation of laboratory results by licensed physicians. Our therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs.

Business Risks and Uncertainties and Other Factors Affecting Our Performance

Our business and prospects are exposed to numerous risks and uncertainties, as described below and in our 2024 Annual Report. For more information, see “Item 1A. Risk Factors” in Part I of the 2024 Annual Report. In addition, our performance in any period is affected by a number of other factors. See the description of some of the material factors affecting our performance in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of the 2024 Annual Report.

Changes in International Trade Policy

The majority of our materials, equipment and reagents are sourced in the United States, or locally where our testing services are performed or processed. While we do not believe we have been materially affected by the recent tariffs or changes in U.S. trade policy, tariffs, quotas, trade agreements or other trade restrictions imposed by the U.S. or other governments could increase our costs and the costs of those in our supply chains who may then seek to pass all or a portion of those costs on to us. These increases in turn may adversely affect our margins and results of operations.

Results of Operations

The table below summarizes the results of our continuing operations for each of the periods presented. For a financial overview relating to our results of operations, including general descriptions of the make-up of material line items of our statement of operation data, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of the 2024 Annual Report.


	Three Months Ended March 31,
	2025			2024			$ Change			% Change
	(in thousands, except percentages)
Statement of Operation Data
Revenue	$	73,463		$	64,485		$	8,978			14	%
Cost of revenue		45,117			42,381			2,736			7	%
Gross profit		28,346			22,104			6,242			28	%
Operating expenses
Research and development		12,395			11,434			961			8	%
Selling and marketing		8,465			8,989			(524	)		(6	)%
General and administrative		25,291			21,489			3,802			18	%
Amortization of intangible assets		1,990			1,990			—			0	%
Total operating expenses		48,141			43,902			4,239			10	%
Operating loss		(19,795	)		(21,798	)		2,003			(9	)%
Other income (expenses)
Interest income		8,018			7,385			633			9	%
Interest expense		(14	)		249			(263	)		(106	)%
Other income (expense), net		68			(9	)		77			(856	)%
Total other income, net		8,072			7,625			447			6	%
Loss before income taxes		(11,723	)		(14,173	)		2,450			(17	)%
Provision for (benefit from) income taxes		176			(327	)		503			(154	)%
Net loss from consolidated operations		(11,899	)		(13,846	)		1,947			(14	)%
Net loss attributable to noncontrolling interests		369			384			(15	)		(4	)%
Net loss attributable to Fulgent	$	(11,530	)	$	(13,462	)	$	1,932			(14	)%

Revenue


	Three Months Ended March 31,
	2025		2024		$ Change			% Change
	(in thousands, except percentages)
Revenue from laboratory services
Precision diagnostics	$	44,097	$	37,446	$	6,651			18	%
Anatomic pathology		25,300		23,107		2,193			10	%
BioPharma services		4,066		2,656		1,410			53	%
COVID-19		—		1,276		(1,276	)		(100	)%
Total laboratory services	$	73,463	$	64,485	$	8,978			14	%

Revenue increased by $9.0 million, or 14%, from $64.5 million in the three months ended March 31, 2024, to $73.5 million in the three months ended March 31, 2025. The increase in revenue between periods was driven by increases of $6.7 million in precision diagnostics, $2.2 million in anatomic pathology, and $1.4 million in BioPharma services, partially offset by a decrease of $1.3 million in COVID-19 testing.

The increase in precision diagnostics revenue was driven by growth in our reproductive health services and continued strength in legacy diagnostic offerings. Anatomic pathology services revenue increased primarily due to the absence of weather-related disruptions and client losses that had affected the prior year, in addition, the investment that we have made in digital pathology is starting to show return. BioPharma services revenue increased largely as a result of the timing of service projects, though this revenue is expected to remain variable due to the long sale cycles and fluctuations in project timing. Additionally, COVID-19 related revenue recognized in 2024 was due to variable consideration recognized for services completed in prior periods.

We believe the factors that will affect our ability to grow these revenue streams are 1) the average price point we offer and the reimbursement rate from insurance payors; 2) the concentration of our payor base; 3) the competitive advantage we have due to our broad and flexible test menu, detection rate, and turnaround times; and 4) growth in size of an addressable market. Estimated collection amounts from insurance payors are subject to the complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs. Because our proprietary technology platform allows for rapid scaling of a broad, flexible testing menu, we can offer our customers more scalable and affordable testing. Going forward, we will strive to maintain this competitive advantage and emphasize this in our marketing efforts to grow our testing revenue.

Our customer base includes insurance, institutional, and individual payors. In some periods, our revenue is concentrated on a smaller number of customers. For the laboratory services segment, aggregating customers that are under common control, one customer comprised $17.6 million, or 24%, of our revenue in the three months ended March 31, 2025, and $12.6 million, or 20%, of our revenue in the three months ended March 31, 2024. To reduce this revenue risk, we will focus on increasing the number of customers and thereby reducing the concentration.

Revenue from non-U.S. sources decreased by $1.0 million, or 15%, from $6.6 million in the three months ended March 31, 2024, to $5.6 million in the three months ended March 31, 2025. The decrease was primarily due to a one-time licensing arrangement recognized in the prior period that did not recur in the current period.

Cost of Revenue


	Three Months Ended March 31,
	2025			2024			$ Change		% Change
	(in thousands, except percentages)
Cost of revenue	$	45,117		$	42,381		$	2,736		7	%
Cost of revenue as a % of revenue		61	%		66	%

Our consolidated cost of revenue increased by $2.7 million, or 7%, from $42.4 million in the three months ended March 31, 2024, to $45.1 million in the three months ended March 31, 2025. The increase was primarily due to increases of $1.1 million in personnel expenses due to increased headcount, $0.9 million in reagent and supply costs, $0.9 million in facility expenses, $0.4 million in software and software licensing, and partially offset by a decrease of $0.7 million in shipping and handling expenses.

Our consolidated cost of revenues as a percentage of revenue decreased from 66% in the three months ended March 31, 2024, to 61% in the three months ended March 31, 2025. Our gross profit increased by $6.2 million, or 28%, from $22.1 million in the three months ended March 31, 2024, to $28.3 million in the three months ended March 31, 2025. Our gross profit as a percentage of revenue, or gross margin, increased from 34% in the three months ended March 31, 2024, to 39% in the three months ended March 31, 2025. This is driven by the increased revenue and efforts of optimizing cost structures.

Research and Development


	Three Months Ended March 31,
	2025		2024		$ Change			% Change
	(in thousands, except percentages)
Research and development
Laboratory services	$	7,082	$	7,321	$	(239	)		(3	)%
Therapeutic development		5,313		4,113		1,200			29	%
Total research and development	$	12,395	$	11,434	$	961

For the laboratory services segment, the research and development expenses were mainly for advancing our technology and future testing and testing services and decreased between periods, as more research and development spending was focused on the therapeutic development segment.

In three months ended March 31, 2025, the research and development expenses, for the laboratory services segment, primarily consisted of $6.3 million in personnel expenses, including bonuses and equity-based compensation, $0.4 million in reagent and supply costs, $0.1 million in facility expenses, and $0.1 million in depreciation expense. The three months ended March 31, 2024, expenses primarily consisted of $6.6 million in personnel expenses, including bonuses and equity-based compensation, $0.3 million in reagent and supply costs, $0.1 million in facility expenses, $0.1 million in depreciation expense, and $0.1 million in software and licensing fees.

For the therapeutic development segment, the research and development expenses in three months ended March 31, 2025, included $2.6 million in CRO costs, $2.4 million in personnel costs, including equity-based compensation, and $0.2 million in depreciation expenses. In the three months ended March 31, 2024, these expenses comprised $2.3 million in CRO costs, $1.6 million of personnel expenses, including equity-based compensation, and $0.2 million in depreciation expenses.

Research and development expenses for the therapeutic development segment increased by $1.2 million, or 29%, from $4.1 million in the three months ended March 31, 2024, to $5.3 million in the three months ended March 31, 2025. The increase was primarily driven by increases of $0.9 million in personnel costs, including equity-based compensation expense, and $0.3 million in CRO costs. The overall increase was attributed to the advancement and continuation of the clinical study of FID-007, along with FID-022. In three months ended March 31, 2025, approximately $1.0 million was incurred for the preclinical development of FID-022, whereas related costs in the three months ended March 31, 2024, were minimal. Expenses for our therapeutic development segment will be influenced by our ability to progress our therapeutic candidates through development with the FDA, the timing of which can be uncertain and delayed due to a variety of factors beyond our control, including recently announced staff reductions at the FDA which may affect the FDA’s ability to provide any required approvals or review in a timely manner or in the timelines expected.

Looking ahead, we expect research and development expenses to continue increasing as clinical trials progress for FID-007, FID-022, and other preclinical studies.

Selling and Marketing

Our consolidated selling and marketing expenses decreased by $0.5 million, or 6%, from $9.0 million in the three months ended March 31, 2024, to $8.5 million in the three months ended March 31, 2025. The decrease in consolidated selling and marketing expenses was due to decreases of $0.3 million in personnel expenses and $0.2 million in software licensing.

General and Administrative

Our consolidated general and administrative expenses increased by $3.8 million, or 18%, from $21.5 million in the three months ended March 31, 2024, to $25.3 million in the three months ended March 31, 2025. The increase in consolidated general and administrative expenses was due to increases of $4.6 million in provision for credit losses, $1.0 million in personnel costs, partially offset by decreases of $1.1 million in facility expenses and $0.8 million in depreciation expenses.

Amortization of Intangible Assets

Our consolidated amortization of intangible assets represents amortization expenses on the intangible assets that arose from the business combinations in 2022 and 2021, and a patent purchased in 2021. The Company did not have any new business combinations in the current period.

Other Income (Expenses)

Other income, net, is primarily comprised of interest income, which was $8.0 million in the three months ended March 31, 2025, and $7.4 million in the three months ended March 31, 2024. This interest income included interest earned on marketable securities and realized gain or loss on sale of marketable securities. The change in interest income was primarily due to net loss realized from sale of marketable securities in prior year.

Provision for (Benefit from) Income Taxes

Provision for income taxes was $0.2 million for the three months ended March 31, 2025, compared with benefit from income taxes of $0.3 million for the three months ended March 31, 2024. The effective tax rate was (2%) the three months ended March 31, 2025, compared to 2% for the three months ended March 31, 2024. The change in the effective tax rate compared to prior period is due to the valuation allowance in the current period that precludes us from recognizing the benefit from our net operating losses.

Net Loss Attributable to Noncontrolling Interest

Net loss attributable to noncontrolling interest represents net loss attributable to minority shareholders from entities not wholly owned.

Liquidity and Capital Resources

Liquidity and Sources of Cash

We had $814.6 million and $828.6 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2025, and December 31, 2024, respectively. Our marketable securities primarily consist of U.S. government and U.S. agency debt securities, U.S. treasury bills, corporate bonds, municipal bonds, and Yankee debt securities as of March 31, 2025, and December 31, 2024.

Our main uses of cash are for capital expenditures, primarily in buildings, building improvements, and equipment, as well as for stock repurchases, supporting our operations, and to fund strategic acquisitions as we continue to invest in and seek to grow our business. Cash used to cover operating expenses is impacted by the timing of our expense payments, as reflected in the changes in our outstanding accounts payable and accrued expenses.

We expect our existing cash, cash equivalents, restricted cash, and short-term marketable securities will continue to be sufficient to meet our anticipated cash requirements for at least the next 12 months. Cash provided by operations has significantly contributed to our ability to meet our liquidity needs, including paying for capital expenditures, however, cash provided by our operations has in the past experienced fluctuations from period to period, which we expect may continue in the future. These fluctuations can occur because of a variety of factors, including, among others, factors relating to the demand for our tests, the amount and timing of sales, the prices we charge for our tests due to changes in product mix, customer mix, general price degradation for tests, or other factors, the rate and timing of our billing and collections cycles and the timing and amount of our commitments and other payments. We intend to improve our profitability by improving margins and expanding in new markets for our tests, but these efforts are subject to risks, including those described in Item 1A of the 2024 Annual Report, and may not be successful. Moreover, even if our liquidity expectations are correct, we may still seek to raise additional capital through securities offerings, credit facilities or other debt financings, asset sales or collaborations or licensing arrangements.

If we raise additional funds by issuing equity securities, our existing stockholders could experience substantial dilution. Additionally, any preferred stock we issue could provide for rights, preferences or privileges senior to those of our common stock, and our issuance of any additional equity securities, or the possibility of such an issuance, could cause the market price of our common stock to decline. The terms of any debt securities we issue or borrowings we incur, if available, could impose significant restrictions on our operations, such as limitations on our ability to incur additional debt or issue additional equity or other restrictions that could adversely affect our ability to conduct our business, and would result in increased fixed payment obligations. If we seek to sell assets or enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms or relinquish or license to a third-party our rights to important or valuable technologies or tests we may otherwise seek to develop ourselves. Moreover, we may incur substantial costs in pursuing future capital, including investment banking, legal and accounting fees, printing and distribution expenses and other similar costs. Additional funding may not be available to us when needed, on acceptable terms or at all. If we are not able to secure funding if and when needed and on reasonable terms, we may be forced to delay, reduce the scope of or eliminate one or more sales and marketing initiatives, research and development programs or other growth plans or strategies. In addition, we may be forced to work with a partner on one or more aspects of our tests or market development programs or initiatives, which could lower the economic value to us of these tests, programs or initiatives. Any such outcome could significantly harm our business, performance and prospects.

Cash Flows

The following table summarizes our cash flows from continuing operations for each of the periods presented:


	Three Months Ended March 31,
	2025			2024
	(in thousands)
Net cash (used in) provided by operating activities	$	(4,431	)	$	7,266
Net cash provided by (used in) investing activities	$	27,729		$	(47,186	)
Net cash used in financing activities	$	(11,172	)	$	(2,807	)

Operating Activities

During the three months ended March 31, 2025, our operations used $4.4 million of cash, as compared to $7.3 million provided in the three months ended March 31, 2024. The decrease in cash from operating activities in the three months ended March 31, 2025, as compared with the corresponding period in 2024 was primarily due to the timing of cash receipts from customers and cash payments for operating expenses, including bonus expenses. We expect to incur more operating expenses and use more cash in operating activities in the coming quarters as a result of our planned and ongoing clinical trials for FID-007 and FID-022, and as we continue to invest resources to grow our laboratory services business.

Investing Activities

The cash provided by or used in investing activities are impacted by capital expenditures for operation needs and timing of payments, timing of maturities of marketable securities, and discretionary business combinations and other investment.

Cash provided by investing activities in the three months ended March 31, 2025, was $27.7 million, which primarily represents $32.4 million in the maturities of marketable securities, partially offset by $4.7 million related to the purchase of fixed assets consisting mainly of building improvement, medical laboratory equipment, and computer hardware.

Cash used in investing activities in the three months ended March 31, 2024, was $47.2 million, which primarily represents $195.7 million in purchase of marketable securities and $4.1 million related to the purchase of fixed assets consisting mainly of building improvement and medical laboratory equipment, partially offset by $95.5 million related to maturities of marketable securities and $56.9 million related to proceeds from the sale of marketable securities.

Financing Activities

Cash used in financing activities in the three months ended March 31, 2025, was $11.2 million, which primarily related to $8.7 million used in the repurchase of common stock and $1.9 million used in common stock withholding for employee tax obligations.

Cash used in financing activities in the three months ended March 31, 2024, was $2.8 million, which primarily related to $1.7 million used in common stock withholding for employee tax obligations and $0.8 million used in the repayment of notes payable.

We did not expect to use any credit facilities due to the strong cash position as of March 31, 2025.

Stock Repurchase Program

In March 2022, our Board of Directors authorized a $250.0 million stock repurchase program. The stock repurchase program has no expiration from the date of authorization. Under the stock repurchase program, the Company may repurchase shares from time to time in the open market or in privately negotiated transactions.

During the three months ended March 31, 2025, we repurchased 0.5 million shares of our common stock at an aggregate cost of $7.9 million under the stock repurchase program. As of March 31, 2025, an additional $0.8 million was paid for 47,000 shares of our common stock, however the transaction was not settled until early April 2025. During the three months ended March 31, 2024, we repurchased 10,000 shares of our common stock at an aggregate cost of $0.2 million under the stock repurchase program. As of March 31, 2025, a total of approximately $141.8 million remained available for future repurchases of our common stock under our stock repurchase program.

Critical Accounting Policies and Use of Estimates

There have been no material changes to our critical accounting policies or estimates from the information provided in Part II, “Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in the 2024 Annual Report.

Recent Accounting Pronouncements

See Note 2, Summary of Significant Accounting Policies, to our condensed consolidated financial statements included in this report for information about recent accounting pronouncements.

Off-Balance Sheet Arrangements

We did not have, and do not currently have, any off-balance sheet arrangements during the periods presented, as defined in the rules and regulations of the SEC, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

For quantitative and qualitative disclosures about market risk, see Part II, “Item 7A, Quantitative and Qualitative Disclosures About Market Risk,” in our 2024 Annual Report. There were no material changes during the three months ended March 31, 2025.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. As required by Rule 13a-15(b) under the Exchange Act, our management, with the participation of our principal executive officer and principal financial officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures as of March 31, 2025. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2025.

Changes in Internal Control over Financial Reporting

There have not been any changes in our internal control (as required by Rule 13a-15(b) under the Exchange Act) over the financial reporting during the three months ended March 31, 2025, that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

Inherent Limitations on Disclosure Controls and Procedures and Internal Control over Financial Reporting

Management recognizes that any controls and procedures, no matter how well-designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Because of these inherent limitations, our disclosure and internal controls may not prevent or detect all instances of fraud, misstatements or other control issues. In addition, projections of any evaluation of the effectiveness of disclosure or internal controls to future periods are subject to risks, including, among others, that controls may become inadequate because of changes in conditions or that the degree of compliance with policies or procedures may deteriorate.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. As disclosed in Note 8, Debt, Commitments, and Contingencies, to the condensed consolidated financial statements, we are engaged in certain legal investigations, audits, and voluntary disclosure processes, and the disclosure set forth in Note 8 relating to these certain legal matters is incorporated herein by reference.

The outcome of these matters are inherently uncertain, and there can be no assurances that favorable outcomes will be obtained.

Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, and reputational harm, among other factors.

Item 1A. Risk Factors.

Except as set forth below, there have been no material changes to the risk factors set forth in Part I, “Item 1A, Risk Factors,” of the 2024 Annual Report.

Changes in U.S. trade policy and the impact of tariffs may have a material adverse effect on our business, results of operations and financial condition.

While we do not believe our business has been materially affected by the recent tariff environment and recent developments in U. S. trade policy as of the date of this Quarterly Report, our business, results of operations, and financial condition may be adversely affected by uncertainty and changes in U.S. trade policies, including tariffs, quotas, trade agreements, or other trade restrictions imposed by the U.S. or other governments. For example, in April 2025, the U.S. government announced a 10% tariff on product imports from almost all countries and individualized higher tariffs on certain other countries. Several tariff announcements have been followed by announcements of limited exemptions, revisions, and temporary pauses, resulting in significant uncertainty.

While the majority of our equipment, materials and reagents are sourced in the United States, or locally where our testing services are performed or processed, our supply chain and international operations could be adversely affected by changes in U.S. trade policies. Any imposition of, or increase in, tariffs or other restrictions on imports of reagents, equipment, or other materials (or the components of these materials) could increase the cost for such materials and also increase the prices for such materials available domestically or locally, if any, which in turn could increase our costs. We would likely be unable to pass all or potentially any such cost increases on to our customers, and such cost increases could materially and adversely affect our business results of operations and financial condition, including our gross margins. Tariffs or other trade restrictions may lead to continuing uncertainty and volatility in U.S. and global financial and economic conditions and commodity markets, declining consumer confidence, significant inflation, and diminished expectations for the economy. Such conditions could also have a material adverse impact on our business, results of operations and financial position.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Use of Proceeds from Registered Securities

To date, we have used $208.9 million of the net proceeds from sales of our common stock, of which, $4.5 million was used for contributions to FF Gene Biotech, prior to the FF Gene Biotech acquisition; $188.6 million was used to fund the Company’s operations and a business combination; and $15.8 million was used to pay off the investment margin loan. All other net proceeds from sales of our common stock are invested in investment-grade and interest-bearing securities, such as U.S. government and U.S. agency debt securities, corporate bonds, and municipal bonds. There has been no material change in the planned use of proceeds from the sales of our common stock from that described in the applicable prospectus.

Information on Share Repurchases

All purchases listed below were made in the open market at prevailing market prices and were executed pursuant to trading plans we adopted pursuant to Rule 10b5-1 under the Exchange Act.

The number of shares of common stock repurchased by the Company under the stock repurchase program and the average price paid per share for the three months ended March 31, 2025, are as follows:


Period	(a) Total Number of Shares Repurchased		(b) Average Price Paid Per Share (1)		(c) Total Number of Shares Repurchased as Part of Publicly Announced Plans or Programs		(d) Maximum Dollar Value of Shares that May Yet Be Repurchased Under the Plans or Programs
January 2025 (1/1/2025-1/31/2025)		30,000	$	16.85		30,000	$	149,870,000
February 2025 (2/1/2025-2/28/2025)		155,000	$	16.56		155,000	$	147,309,000
March 2025 (3/1/2025-3/31/2025)		284,000	$	16.97		284,000	$	142,491,000
Total		469,000				469,000

(1) Includes commissions for the shares repurchased under the stock repurchase program.

As of March 31, 2025, an additional $0.8 million was paid for 47,000 shares of its common stock, for an average price paid per share of $16.87. However, the transaction was not settled until early April 2025. As of March 31, 2025, a total of approximately $141.8 million remained available for future repurchases of our common stock under the stock repurchase program.

Item 5. Other Information

Rule 10b5-1 trading arrangements

During the three months ended March 31, 2025, none of our directors or officers adopted or terminated “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.

Item 6. Exhibits.

The information required by this Item 6 is set forth on the Exhibit Index immediately preceding the signature page of this report and is incorporated herein by reference.

EXHIBIT INDEX


			Incorporated by Reference
Exhibit No.	Exhibit Title	Filed with this Form 10-Q	Form	Form No.	Date Filed

3.1	Certificate of Incorporation of the registrant, as amended.		10-Q	001-37894	8/14/2017

3.1.1	Certificate of Amendment to Certificate of Incorporation of the registrant, dated August 2, 2016.		10-Q	001-37894	8/14/2017

3.1.2	Certificate of Amendment to Certificate of Incorporation of the registrant, dated May 17, 2017.		10-Q	001-37894	8/14/2017

3.2	Amended and Restated Bylaws of the registrant.		10-Q	001-37894	8/4/2023

10.1#	Amended and Restated Director Compensation Program	X

31.1^	Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	X

31.2^	Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	X

32.1*	Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	X

101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.	X

101.SCH	Inline XBRL Taxonomy Extension Schema Document.	X

101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.	X

101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.	X

101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.	X

101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.	X

104	Cover Page Interactive Data File (embedded within the Inline XBRL document).	X

^ Filed herewith.

* Furnished herewith.

# Management contract or compensatory plan, contract or arrangement Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SIGNATURES


	FULGENT GENETICS, INC.

Date: May 2, 2025	By:	/s/ Ming Hsieh
		Ming Hsieh
		Chief Executive Officer (principal executive officer)

Date: May 2, 2025	By:	/s/ Paul Kim
		Paul Kim
		Chief Financial Officer (principal financial and accounting officer)

EX-10.1 2 flgt-ex10_1.htm EX-10.1 EX-10.1

Exhibit 10.1

FULGENT GENETICS, INC.

AMENDED AND RESTATED

DIRECTOR COMPENSATION PROGRAM

This Amended and Restated Director Compensation Program (this “Program”) sets forth the compensation payable to directors of Fulgent Genetics, Inc., a Delaware corporation (the “Company”), as consideration for their service as directors of the Company. This Program does not constitute a legally binding contract or arrangement and may be changed or rescinded at any time upon the approval of the Company’s Board of Directors (the “Board”).

A. Cash Compensation and Reimbursement.

1. Each director of the Company (each, a “Director”) shall receive reimbursement in cash for his or her reasonable out-of-pocket costs and travel expenses incurred in connection with attendance at meetings of the Board and the committees of the Board (the “Committees”) of which such Director is a member, which reimbursement shall be paid by the Company within thirty (30) days after the Company’s receipt of a Director’s request for reimbursement and reasonable evidence of such costs and expenses.

2. Each Director that is not an employee of the Company or any of its affiliates (each, a “Non-Employee Director”) shall receive the following annual cash retainer fees (collectively, the “Cash Retainer Fees”) based on his or her service as a Director, Chair of a Committee and/or member of a Committee:



		Cash Retainer Fee Amount(1)
Annual Director Cash Retainer Fee:
Each Non-Employee Director	$	90,000

Annual Committee Chair Cash Retainer Fees:(2)
Audit Committee Chair	$	15,000
Compensation Committee Chair	$	10,000
Nominating Committee Chair	$	6,000

Annual Committee Member Cash Retainer Fees:(2)
Audit Committee Member	$	7,500
Compensation Committee Member	$	5,000
Nominating Committee Member	$	3,000

____________

(1) Directors, Committee Chairs and Committee members receive pro-rated amounts of all applicable Cash Retainer Fees for any partial year of service in any such position.

(2) Cash Retainer Fees for Committee Chair and Committee member positions are in addition to the Cash Retainer Fee for service as a Director.

All Cash Retainer Fees earned by a Non-Employee Director for service as a director during a fiscal year shall be paid by the Company bi-annually, within thirty (30) days after the end of the second and fourth fiscal quarters of such fiscal year.

B. Equity Compensation.

1. Subject to the approval of the administrator under the applicable Plan (as defined below), on the date of his or her election or appointment as a Director, each Non-Employee Director shall be granted the following equity award or awards (such award or awards, the “Initial Award”): (i) a non-qualified stock option award (“Option”) to acquire up to a number of shares of the Company’s common stock having an aggregate grant date fair market value equal to the applicable Available Amount (as defined below), based on a Black-Scholes valuation method (rounded down to the nearest whole share); (ii) a restricted stock unit award (“RSU”), each RSU relating to one share of the Company’s common stock, having an aggregate fair market value equal to the applicable Available Amount pursuant to the terms of the then applicable equity incentive plan for such grants, assuming the closing price of the Company’s common stock on the date of grant; or (iii) an Option and a RSU to acquire or relating to, as applicable, such that the sum of the aggregate fair market value of the Option and RSU, each as determined herein, is equal to the applicable Available Amount.

2. Subject to the approval of the administrator under the applicable Plan, on the date of each Annual Meeting of the Stockholders of the Company, each Non-Employee Director that is serving as such immediately prior to and immediately after the applicable Annual Meeting of the Stockholders shall be granted the following equity award or awards (such award or awards, the “Annual Award”): (i) an Option to acquire up to a number of shares of the Company’s common stock having an aggregate grant date fair market value equal to the applicable Available Amount, valued based on a Black-Scholes valuation method (rounded down to the nearest whole share); (ii) a RSU, each RSU relating to one share of the Company’s common stock, having an aggregate fair market value equal to the applicable Available Amount, assuming the closing price of the Company’s common stock on the date of grant; or (iii) an Option and a RSU to acquire or relating to, as applicable, a number of shares of the Company’s common stock such that the sum of the aggregate fair market value of the Option and RSU, as determined herein, is equal to the applicable Available Amount.

3. In addition to the Initial Award and the Annual Award, directors shall be eligible to receive such additional equity awards in such amounts and on such dates and subject to such terms as the Board and/or any appropriate Committees may approve.

4. For purposes of this Program, the “Available Amount” for all Initial Awards and Annual Awards shall be as follows:



		Available Amount
Initial Award		$400,000
Annual Award		$180,000

All Initial Awards and Annual Awards (referred to collectively as the “Awards”) shall be granted under and subject to the Company’s 2016 Omnibus Incentive Plan or such other comparable equity incentive plan of the Company that is then in effect (such applicable plan, the “Plan”) and shall be subject to the following terms: (i) each Award that is a non-qualified stock option shall expire after 10 years; (ii) each Initial Award shall commence vesting on the date of the appointment or election of the applicable Non-Employee Director, and each Annual Award shall commence vesting on the date of the applicable Annual Meeting of Stockholders of the Company; (iii) each Award shall vest as follows: one-quarter of the total shares of the Company’s common stock subject to the Award shall vest one year after the vesting commencement date of the Award and 1/16th of the total shares of the Company’s common stock subject to the Award shall vest at the end of every three-month period thereafter, subject to the applicable Non-Employee Director’s continued service for the Company on each such vesting date; and (iii) each Award shall be subject to all other terms set forth in the applicable form of award agreement under the Plan that has been approved by the Board.

EX-31.1 3 flgt-ex31_1.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Ming Hsieh, certify that:

I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 of Fulgent Genetics, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: May 2, 2025	By:	/s/ Ming Hsieh
		Ming Hsieh
		Chief Executive Officer
		(principal executive officer)

EX-31.2 4 flgt-ex31_2.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Paul Kim, certify that:

I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 of Fulgent Genetics, Inc.;

(a)

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: May 2, 2025	By:	/s/ Paul Kim
		Paul Kim
		Chief Financial Officer
		(principal financial and accounting officer)

EX-32.1 5 flgt-ex32_1.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 of Fulgent Genetics, Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned hereby certifies in his capacity as the specified officer of the Company, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 2, 2025	By:	/s/ Ming Hsieh
		Ming Hsieh
		Chief Executive Officer
		(principal executive officer)

Date: May 2, 2025	By:	/s/ Paul Kim
		Paul Kim
		Chief Financial Officer
		(principal financial and accounting officer)

This certification accompanies the Quarterly Report on Form 10-Q to which it relates and shall not be deemed filed with the Securities and Exchange Commission or incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.